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ABSTRACT 
 
 
The zinc finger-encoding transacting factor EKLF, or erythroid Krüppel-like 
factor, binds key regulatory elements of many erythroid-specific genes, and is essential 
for definitive erythropoiesis. Mice lacking this factor die of anemia by E15.5 of gestation, 
failing to activate β-globin gene transcription, and demonstrating a block in the erythroid 
differentiation program at the primitive erythroblast stage. In contrast, megakaryocytic 
progenitors are amplified in EKLF-null embryos, with increased Fli-1 gene expression, a 
marker of early megakaryocytic differentiation.  These observations are consistent with 
the idea that EKLF modulates the megakaryocytic-erythroid (M-E) differentiation switch.  
 
Our laboratory has previously demonstrated that an amino terminal sequence of 
EKLF (Δ221EKLF) is required to induce chromatin remodeling at the β-globin promoter 
in an EKLF-null erythroid cell line.  However, additional amino terminal sequences are 
required for initiation of β-globin gene transcription.  To evaluate the role of this 
chromatin remodeling domain in erythroid and megakaryocytic differentiation in vivo, I 
have generated a knock-in allele of Δ221EKLF.  Using the recombineering method, a 
lambda phage-based homolgous recombination method in E. coli, cDNA encoding the 
Δ221EKLF domain has been inserted into the endogenous initiation site, thus placing the 
mutant protein under the cis-regulatory elements of the endogenous murine EKLF locus. 
Subsequently, Δ221EKLF alleles have been generated by gene targeting in ES cells.  I 
have used the mice to probe the in vivo role of Δ221EKLF in definitive hematopoietic 
cells. 
 
Similar to EKLF-null embryos, mice homozygous for the Δ221EKLF mutant 
allele die of anemia by E15.5 of gestation.  Molecular analysis of Δ221EKLF 
erythroblasts reveals i) a failure to activate β-globin gene transcription; ii) lack of GATA-
1 and NF-E2 recruitment to the β-globin promoter; iii) a block in terminal erythroid 
differentiation.  In contrast to erythroid cells lacking EKLF, Δ221EKLF erythroid 
progenitors demonstrate appropriate binding of the Δ221EKLF encoding domain to all 
EKLF-regulatory sequences and a chromatin architecture and histone modification 
pattern at erythroid-specific genes that recapitulate the events observed in wild-type 
EKLF erythroblasts at a similar stage of erythroid ontogeny. 
 
Examining the role of Δ221EKLF in megakaryopoiesis, I observed inhibition of 
megakaryocytic progenitor expansion in Δ221EKLF fetal hematopoietic cell populations 
when compared to EKLF-null embryos.  Molecular analysis of Δ221EKLF erythroblasts 
reveals i) binding of the Δ221EKLF mutant protein to the Fli-1 promoter with inhibition 
of gene transcription; ii) hypoacetylation of histone H3 at the Fli-1 promoter; iii) 
recruitment of a Sin3A-containing corepressor complex to the Fli-1 promoter.  Taken 
together, my results suggest strongly that the unique Δ221EKLF domain is sufficient to 
modulate the chromatin-specific roles of EKLF at erythroid- and megakaryocytic-specific 
loci in definitive hematopoietic cells in vivo.  
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CHAPTER 1: INTRODUCTION 
 
 
MOUSE HEMATOPOIESIS 
 
Hematopoiesis is the formation and development of blood cells involving the 
differentiation of a multipotent progenitor, the hematopoietic stem cell (HSC), and its 
progeny into all blood cell lineages (Figure 1.1) (Orkin & Zon, 2008).  This complex 
continuous process requires a broad spectrum of lineage-specific transcription factors 
(TFs), such as SCL, LMO2, c-myb, PU.1, EKLF, GATA-1, NF-E2, and Fli-1 (Shivdasani 
& Orkin, 1996; Perry & Soreq, 2002; Orkin & Zon, 2008).   Genetic studies involving the 
disruption or over-expression of these genes have facilitated our understanding of the 
transcriptional regulation of hematopoiesis (Perry & Soreq, 2002).  Many of these TFs 
are beyond the scope of my dissertation and will not be addressed.   In the context of this 
dissertation, I will explore the role of erythroid-Krüppel-like factor, or EKLF, in β-globin 
gene regulation during erythroid differentiation (Chapter 3).  Furthermore, I will 
demonstrate that the chromatin remodeling encoding domain of EKLF is sufficient to 
repress expansion of megakaryocytic progenitors observed with complete loss of EKLF 
(Chapter 4).   
 
 
Overview of erythropoiesis 
 
 Erythropoiesis is the development of mature red blood cells from hematopoietic 
stem cells (Orkin & Zon, 2008).  In mammals, this process occurs in the bone marrow 
and is characterized by three stages (Palis, 2009).  The first stage involves production of 
lineage –committed progenitors.  The earliest recognizable erythroid-specific progenitor 
is the burst-forming unit erythroid (BFU-E).  The BFU-E generates more mature 
erythroid-committed progenitors termed colony-forming units erythroid (CFU-E) 
(Socolovsky et al., 1998).  BFU-E and CFU-E can be detected in vitro using colony-
forming assays (Ogawa et al., 2002).  The second stage of erythroid differentiation 
consists of the progression of erythroid precursors from early proerythroblasts into 
orthochromatic erythroblasts.  This stage of erythroid differentiation is characterized by 
the progressive accumulation of hemoglobin, expansion of erythroblasts, and progressive 
nuclear pyknosis and ultimately loss of the nucleus.  The final stage of erythropoiesis 
involves maturation of the young red blood cells (reticulocytes) into mature circulating 
red cells (Palis, 2009). 
 
Erythropoiesis occurs in distinct phases and anatomic sites during murine 
development (Dzierzak & Medvinsky, 1995; Zon, 1995; Shivdasani & Orkin, 1996; Palis, 
2008).  The first phase can be identified in the yolk sac at embryonic day 7.5 (E7.5) in 
mice and is referred to as primitive or embryonic erythropoiesis.  Primitive erythrocytes 
are large cells that retain their nuclei and produce embryonic globin chains (ζ, ε/βh1). 
The adult β-globin genes are silent.  By E11, definitive erythropoiesis is initiated in the 
fetal liver.  At this stage, the adult globin (α, βmaj/βmin) genes are expressed and the 
embryonic globin genes are silenced.  The molecular mechanisms regulating the  
 1
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Figure 1.1. Overview of murine hematopoiesis.  All blood cell types arise from the 
self-renewing hematopoietic stem cell (HSC) that differentiates into committed 
progenitor cells to produce mature blood cells.  The erythroid and megakaryocytic 
lineage is thought to have come from a common bipotent progenitor (megakaryocytic-
erythroid progenitor (MEP) (dotted box).  The MEP population is thought to be formed 
from common myeloid progenitor (CMP); recent evidence proposes a direct pathway 
from HSCs to MEP (dotted line).  Key transcription factors regulating this process are 
listed by the cell type in which they are expressed.  Abbreviations: MPP, multipotent 
progenitor; CLP, common lymphoid progenitor; GMP, granulocyte and macrophage 
progenitor; CFU-G, colony-forming unit granulocyte; CFU-M, colony-forming unit 
monocyte/macrophage; BFU-E, blast-forming unit erythrocyte; CFU-E, colony-forming 
unit erythrocyte; MK-P, megakaryocyte progenitor. 
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switching of globin gene expression has been the intense focus of many laboratories.  
They have provided a critical foundation for our understanding of the molecular 
mechanism underpinning erythropoiesis. 
 
 
Overview of megakaryopoiesis 
  
The erythroid and megakaryocyte lineages are thought to be derived from a 
common precursor, the bipotent megakaryocyte-erythroid progenitor (MEP) (Debili et al., 
1996).  In the most established pathway, HSCs generate common myeloid progenitor 
(CMP) cells from which the MEP is formed (Akashi et al., 2000).  However, it has been 
recently proposed that HSCs can give rise to MEP population without an intermediate 
progenitor (Adolfsson, 2005). 
 
Megakaryopoiesis is the process by which HSCs differentiate into mature 
megakaryocytes through a series of differentiated progenitors.  Megakaryocytic 
progenitors are detected in the yolk sac and fetal liver at approximately E7.5-10.5 and 
E11.5, respectively (Tober et al., 2007).  The earliest committed MK progenitor is the 
burst-forming unit megakaryocyte (BFU-MK) that gives rise to the more mature colony-
forming unit megakaryocyte (CFU-MK) (Briddellet al., 1989).  The CFU-MK then gives 
rise to megakaryoblasts that in turn differentiate into mature megakaryocytes.  
 
 
Transcription factors in erythropoiesis and megakaryopoiesis  
 
The precursor cells express many common hematopoietic transcription factors 
that are essential to both erythropoiesis and megakaryopoiesis, including GATA-1 
(Pevny et al., 1995; Shivdasani et al., 1997), FOG1 (Tsang et al., 1997), and SCL (Hall et 
al., 2003).  The MEP lineage differentiation is regulated in part by the differential 
expression and combinatorial action of these transcription factors. 
  
 
GATA-1 
 
GATA-1, the founding member of the GATA family of zinc finger proteins, is an 
erythroid transcription factor that binds to the DNA sequences WGATAR found at the 
cis-regulatory sequences of nearly all erythroid genes, including the β-globin gene 
(Martin & Orkin, 1990; Weiss & Orkin, 1995).  GATA-1 is also expressed and has 
defined functional activities in megakaryocytes, eosinophils, and mast cells (Zon et al., 
1993).  Hemizygous deletion of GATA-1, located on the X-chromosome, leads to loss of 
erythropoiesis and embryonic lethality by E11.5 (Fujiwara et al., 1996).  GATA-1 null 
mice also display a block in megakaryocyte development.  However, GATA-1 null ES 
cells can develop into other hematopoietic lineages (Kitajima et al., 2006).  Similarly, 
forced expression of GATA-1 in an early myeloid cell line promotes megakaryocytic 
differentiation, suggesting that GATA-1 has a key role in lineage determination 
(Shivdasani & Orkin, 1996; Shivdasani et al., 1997).  Studies to identify proteins that 
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bind to GATA-1 led to the discovery of Friend of GATA (FOG-1), a nuclear zinc finger 
protein that binds the amino zinc finger of GATA-1 (Tsang et al., 1997).  Expression of 
FOG-1 is similar to that of GATA-1.  Like mice lacking GATA-1, FOG-1 null mice do 
not form megakaryocytic progenitors and are embryonic lethal at E11.5 (Tsang et al., 
1998). 
 
 
NF-E2 
  
NF-E2 is a hematopoietic transcription factor belonging to the basic-leucine 
zipper family of dimeric proteins consisting of a ubiquitously expressed 18 kDa subunit 
and a tissue-specific 45 kDa subunit (Chan et al., 1993).  Initial studies in cell lines 
provided evidence that NF-E2 is essential for β-globin gene expression (Lu et al., 1994).  
Surprisingly, mice lacking the 45 kD hematopoietic-restricted subunit develop only a 
mild erythroid phenotype, but exhibit severe thrombocytopenia with bone marrow 
showing excessive immature and dysplastic megakaryocytes (Shivdasani & Orkin, 1995).  
The subtle effects on erythroid maturation are presumably due to functional redundancy 
between NF-E2 and other basic leucine zipper family proteins (Sawado et al., 2001).  By 
contrast, the molecular basis for the severe defects in megakaryocyte differentiation and 
platelet release remains to be elucidated. 
 
 
Fli-1 
 
Fli-1 is a member of the Ets family of transcription factors (Watson et al., 1992) 
containing a conserved winged helix-loop-helix DNA binding (ETS) domain which has 
critical functions in development and oncogenesis (Jackers et al., 2004).  Fli-1 is 
preferentially expressed in cells of the hematopoietic lineages and vascular endothelium.  
Fli-1 has been shown to transcriptionally activate many genes, including those involved 
in megakaryopoiesis.  In undifferentiated hematopoietic cell lines, overexpression of Fli-
1 can induce megakaryocytic features and inhibit erythroid differentiation (Pereira et al., 
1999; Athanasiou et al., 2000). Moreover, Fli-1 knock-out mice either have abnormal 
megakaryocytes with associated thrombocytopenia (Hart et al., 2000) or fail to develop 
recognizable megakaryocytes (Kawada et al., 2001).  These observations are consistent 
with the idea that Fli-1 is a key factor in the lineage fate decision leading to the 
production of megakaryocytes. 
  
Interestingly, these factors are interconnected with my gene of interest, EKLF 
(reviewed in a separate section below).   EKLF, GATA-1, and Fli-1 are all expressed in 
the MEP (Orkin & Zon, 2008).  GATA-1 transcriptionally activates EKLF (Crossley et 
al., 1994), while Fli-1 and EKLF interactions have been noted (Starck et al., 2003).  
Moreover, recent data including that from our laboratory suggest that EKLF represses 
Fli-1 expression (J.M.C unpublished data; Frontelo et al., 2007).  Similarly, both EKLF 
and NF-E2 are essential for high level β-globin gene transcription (Asano & 
Stamatoyannopoulos, 1998; Sawado et al., 2001).  However, the relationship between 
EKLF and NF-E2 in megakaryopoiesis is relatively unknown.  Although associations 
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between these transcription factors and many others are recognized in erythroid and 
megakaryocytic differentiation, the mechanisms underlying these relationships have yet 
to be resolved.   
 
 
ERYTHROID KRÜPPEL-LIKE FACTOR 
 
 
Discovery of EKLF in MEL cell line 
 
The murine erythroleukemia (MEL) cell line has proven a popular and highly 
important murine model system to study erythroid-specific gene expression.  These 
erythroid progenitor cells, immortalized by infection with Friend virus (Friend, 1957; 
Antoniou, 1991), are arrested at the proerythroblast stage of development.  This cell can 
be maintained in tissue culture indefinitely (Friend, 1957; Antoniou, 1991).  However, 
upon treatment with various chemical agents, MEL cells can be induced to undergo 
erythroid differentiation with the induction of globin and other erythroid genes involved 
in the terminal erythroid differentiation program (Marks & Rifkind, 1988; Radhika et al., 
1995). These cells have also proven to be useful to study megakaryocytic differentiation 
(Bouilloux et al., 2008). 
 
 This transformed cell line is an ideal model to identify novel genes which may 
play a role in erythropoiesis.  Using subtractive hybridization and enriching for genes 
expressed in a MEL cell line, but not in a murine monocyte-macrophage cell line, a novel 
erythroid cell-specific zinc finger protein was isolated (Miller & Bieker, 1993).  Close 
inspection of the zinc finger region of this factor revealed that it is similar to the 
Drosophila pattern-determining gap gene Krüppel.  Therefore, the protein was named 
EKLF/KLF1, for erythroid Krüppel-like factor (Miller & Bieker, 1993).   
 
 
Molecular properties of EKLF 
 
EKLF maps to a region on mouse chromosome 8 (Jenkins et al., 1998) and human 
chromosome 19 (Bieker, 1996; van Ree et al., 1997).  The EKLF gene spans ~6.5 kb and 
contains 3 exons.  There are two major transcripts produced, the results of alternative 
transcriptional start sites at nucleotides 41 and 55.  This is not uncommon as multiple 
transcription start sites have been observed for other tissue-specific genes, namely the 
heterogeneous 5’ ends of both c-myb and GATA-1 (Bender & Kuehl, 1986; Tsai et al., 
1989).  Sequence analysis reveals open reading frames beginning at the in-frame 
methionines 1 and 19.  Because methionine 1 does not match the Kozak consensus 
sequence, translation of the major product starts from methionine 19, encoding an EKLF 
protein of 358 amino acids (37,755 Da) (Miller & Bieker, 1993).  The protein has a 
carboxy-terminal DNA-binding domain consisting of three C2H2 zinc fingers and a 
proline-rich amino domain that has structural similarities to other transactivation domains 
(Figure 1.2). 
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Figure 1.2. Domain mapping of murine EKLF.  This schematic diagram summarizes 
the EKLF protein showing its transactivation (amino terminal) and DNA binding 
(carboxyl terminal) regions.  EKLF encodes a protein of 376 amino acids characterized 
by a proline-rich transactivation domain.  The DNA binding domain contains three C2H2 
zinc fingers.  Also noted in the diagram are the locations of important phosphorylation 
(T41), sumoylation (K74), acetylation (K288 and K302), and ubiquitination (throughout 
protein) sites, and two NLS discussed in the text.   
Proline-rich 1 2 3
Cys-His Zn Fingers
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EKLF/KLF1, the founding member of a 15 gene clade, interacts with the DNA 
consensus sequence CCNCNCCCN found at many promoters (Miller & Bieker, 1993). 
EKLF has two nuclear localization signals (NLSs) corresponding to a region adjacent to 
the zinc finger DNA binding domain within a stretch of highly basic amino acids 275-296 
(Quadrini & Bieker, 2002) and another more efficient signal within the zinc finger 
domain itself encompassing amino acids 293-376 (Pandya & Townes, 2002; Quadrini & 
Bieker, 2002).  Interestingly, each zinc finger is important for the overall function of the 
NLSs, and a complete zinc finger structure is necessary for efficient nuclear localization.   
 
 
Expression of EKLF 
 
Both human and murine EKLF have been cloned and show a high degree of 
homology with >90% similarity in the zinc fingers and approximately 70% within the 
proline-rich amino domain (Bieker, 1996; van Ree et al., 1997).  Expression of both 
factors is restricted to the erythroid lineage with high levels in murine and human 
definitive hematopoietic progenitors (Miller & Bieker, 1993; Bieker, 1996; van Ree et al., 
1997).  During in vitro hematopoietic cell differentiation of murine ES cells, EKLF is 
expressed in the CMP and MEP population (Frontelo et al., 2007).  EKLF expression is 
absent in lymphoid cell lines (Miller & Bieker, 1993) and the CLP and their progeny 
(Frontelo et al., 2007).   
 
During murine ontogeny, EKLF is expressed early and at different anatomical 
sites (Southwood et al., 1996).  EKLF mRNA is detected first at the neural plate stage (at 
E7.5) within the blood islands in the yolk sac.  EKLF is then expressed within the hepatic 
tissue beginning with the earliest stage of hepatic formation at E9 and continuing until 
E14.5 when the liver becomes the only source of EKLF.  Concomitantly with EKLF 
mRNA, EKLF protein is also expressed in primitive cells and in the fetal liver.  In the 
adult animal, EKLF expression is strictly localized to the red pulp of the spleen.     
 
 
Regulation of EKLF 
 
EKLF is a stage-and lineage-specific transcription factor, its expression requiring 
tight regulation.  EKLF expression is induced by Bmp4/Smad signaling and GATA-1 
(Adelmann et al., 2002; Lohmann & Bieker, 2008).  However, regulation of EKLF 
activity is achieved in part by post-translational modifications of the EKLF protein (see 
Figure 1.2).  First, EKLF is a phosphoprotein whose transcriptional activity is dependent 
on the phosphorylation status at threonine 41 (T41) (Ouyang et al., 1998).  On the other 
hand, sumoylation of EKLF at lysine 74 (K74) promotes transcriptional repression of 
megakaryopoiesis (Siatecka et al., 2007).  Similarly, EKLF is acetylated by CBP/p300 
(Zhang & Bieker, 1998; Zhang et al., 2001).  This modification increases EKLF’s affinity 
for the SWI/SNF components of chromatin remodeling complexes which has been 
postulated to maintain chromatin in an open configuration (Armstrong et al., 1998; 
Kadam et al., 2000; Zhang et al., 2001).  On the other hand, EKLF acetylation can also 
result in interaction with co-repressors Sin3A and recruitment of histone deacetylases 
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(HDACs) to promoters to inhibit gene transcription (Chen & Bieker, 1996; Chen & 
Bieker, 2004).  Finally, EKLF can be ubiquitinated and degraded through the ubiquitin-
mediated proteosome pathway (Quadrini & Bieker, 2006).   
 
 
The role of EKLF at the β-globin locus 
 
Disruption of the EKLF gene by homologous recombination has demonstrated its 
non-redundant role in erythropoiesis.  EKLF-null embryos die of a lethal anemia by 
embryonic day 16 (E16), as definitive erythroid cells fail to produce β-globin transcripts 
in vivo (Nuez et al., 1995; Perkins et al., 1995), consistent with the idea that EKLF is 
essential for β-globin gene transcription.  However, it is now recognized that EKLF also 
regulates expression of multiple erythroid-specific genes, including cytoskeletal proteins 
(Nilson et al., 2006) and alpha hemoglobin stabilizing protein (AHSP) (Pilon et al., 2006).  
Moreover, analysis of EKLF-null embryos that are transgenic for the human β-globin 
locus confirmed the necessity of EKLF for human β-globin gene transcription (Perkins et 
al., 1996; Wijgerde et al., 1996).  Studies in EKLF-null animals have delineated three 
mechanisms of action for EKLF in regulating β-globin gene transcription: i) chromatin 
remodeling, ii) modulation of transactivation, and iii) stabilization of the locus control 
region (LCR)/β-globin promoter interaction.  
 
 
EKLF alters chromatin structure at the β-globin promoter 
 
Local chromatin structure plays a critical role in regulating gene expression.  
Transcriptionally active genes are typically found in regions of open chromatin structure 
characterized by DNase I-sensitivity and histone hyperacetylation whereas inactive genes 
are packaged in a highly condensed chromatin configuration that is typically DNase I-
insensitive and under-acetylated (Harju et al., 2002).  Chromatin structure may be altered 
by changing the organization of the nucleosome(s) at the gene promoter or by modifying 
the histones (Harju et al., 2002).  Thus, chromatin remodeling is an essential event for the 
initiation of gene transcription in vivo. 
 
EKLF is a key player in activating β-globin gene transcription.  Not only has it 
been postulated to be necessary for transactivation but it was the first factor implicated in 
erythroid-specific promoter remodeling of the β-globin promoter.  Analysis of EKLF-null 
embryos revealed a specific loss of a developmentally specific DNase I hypersensitive 
site in the proximal β-globin promoter (Wijgerde et al., 1996).  Since the degree of 
DNase I hypersensitivity of a given locus correlates with nucleosomal remodeling (Steger 
& Workman, 1996; Pazin et al., 1997), these findings strongly suggest that EKLF is 
required for chromatin reorganization at the β-globin promoter in definitive erythroid 
cells.  A loss of DNase I hypersensitivity was also observed in hypersensitive site 3 
(HS3) of the LCR, but to a lesser extent.  Furthermore, utilizing chromatin 
immunoprecipitation (ChIP) analysis, we observed increased acetylation of histone H3 at 
the β-globin promoter after induction of EKLF in an EKLF-inducible erythroid cell 
system.  This change correlates with activation of β-globin gene transcription (J.M.C 
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unpublished data).  These results confirmed the role of EKLF as a chromatin modulator 
and transcriptional activator of the β-globin gene. However, the specific domains that 
fulfill this role in vivo and the molecular mechanisms responsible for chromatin 
modification remain to be elucidated.  
  
 
EKLF-mediated transactivation 
 
EKLF is an erythroid-specific transcription factor containing a carboxy-terminal 
zinc finger DNA-binding domain and a proline rich amino terminal domain.  Initial 
structure-function studies, utilizing chimeric proteins consisting of the DNA-binding 
domain of the yeast factor GAL4 fused in frame to various EKLF sequences, demonstrate 
that the amino terminal region could be divided into two domains with opposing 
functions (Chen & Bieker, 1996).  In these assays, the first 104 amino acids activate 
GAL4-dependent transcription, whereas an internal domain (aa 196-291) mediated 
transcriptional repression.   In contrast to these studies that utilize heterologous promoters, 
our laboratory has shown that an internal domain of EKLF is sufficient for activation of 
the endogenous β-globin promoter (Brown et al., 2002).  However, it remains unclear 
what functions of EKLF are required for β-globin gene transactivation in vivo. 
 
 
The role of EKLF in LCR/β-globin promoter interaction 
 
Regulation of the β-globin locus is believed to occur in part by competition of 
each globin gene promoter for direct interaction with the LCR with the intervening region 
looping out.  Direct support for EKLF being involved in stabilizing the LCR/β-globin 
promoter interaction was provided by utilizing chromosome conformation capture (3C) 
technology (Dekker et al., 2002) to study the spatial organization of the β-globin locus.  
In erythroid cells, the hypersensitive sites of the LCR are in close physical proximity to 
the active globin genes with the intervening DNA sequence containing the inactive globin 
genes looped out forming the Active Chromatin Hub (ACH), a nuclear compartment 
dedicated to RNA polymerase II mediated transcription (Palstra et al., 2003).  Subsequent 
studies in EKLF-null fetal livers demonstrated that EKLF is required for ACH formation 
and active β-globin gene transcription (Drissen et al., 2004).  Despite the significant 
insights into the binding sites, and the effects of wild-type EKLF action, it remains 
unclear whether differing domains of EKLF are required for alteration of the β-promoter 
and LCR architecture in vivo.  
 
 
Other EKLF target genes 
 
Early observations alluded to a broader role for EKLF in the regulation of genes 
other than β-globin.  First, the EKLF-null phenotype is more severe than that observed in 
a murine model of β-thalassemia in which the adult β-globin genes are deleted by 
homologous recombination (Ciavatta et al., 1995).  Furthermore, enforced expression of 
an EKLF-independent globin transgene fails to rescue the lethal phenotype (Perkins et al., 
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2000).  Gene profiling studies by our laboratory and many others provide a list of 
potential target genes (see Appendix Table A.1).  Subsequent studies utilizing chromatin 
immunoprecipitation (ChIP) analysis have confirmed dematin (Hodge et al., 2006), 
AHSP (Keys et al., 2007; Pilon et al., 2006), ankyrin, Band 3 (Nilson et al., 2006), and 
BKLF (Funnell et al., 2007) as direct EKLF target genes.  Together these observations 
support a broader role for EKLF in the regulation of other erythroid-specific genes and 
provide additional evidence that defects in addition to β-globin deficiency contributes to 
the lethal phenotype in EKLF-null mice. 
 
 
EKLF possesses distinct and separable chromatin remodeling and transactivation 
domains 
  
To explore the determinants of EKLF-dependent β-globin gene activation, our 
laboratory utilized an erythroblast cell line lacking endogenous EKLF expression, 
J2eΔeklf (Coghill et al., 2001).  Briefly, this line was prepared by immortalization of fetal 
liver erythroblasts derived from E14.5 EKLF-null embryo by transduction with a raf/myc 
retrovirus.  Subsequently, the cells were transduced with retroviral constructs containing 
EKLF cDNA fused in frame with the influenza hemagglutinin (HA) epitope at the amino 
terminus and the tamoxifen-binding domain of the estrogen receptor (ERTM) at the 
carboxyl terminus.  Constructs containing full length human EKLF and a series of amino 
terminal mutants were studied (Figure 1.3A) (Coghill et al., 2001; Brown et al., 2002).  
Subsequently, these cell lines were utilized to study the distinct domains of EKLF in β-
globin gene activation. 
 
To determine the effects of the amino terminal deletions on formation of 
hypersensitive sites at the β-globin promoter, nuclei of induced cells for each mutant 
were incubated with increasing amounts of DNase I (Figure 1.3B).  Contrary to an in 
vitro study that demonstrated the DNA binding domain of EKLF alone could induce a 
specific DNase I hypersensitive site of chromatinized β-globin template (Kadam et al., 
2001), the hypersensitive site pattern in J2eΔeklf cells expressing the Δ253EKLF mutant 
is similar to that observed in J2eΔeklf null cells.  In contrast, cells expressing Δ221EKLF 
and Δ164EKLF show a hypersensitive site pattern similar to that observed with full-
length EKLF (flEKLF).  Therefore, the sequence between aa 221-253 is required and 
sufficient for an “open” configuration at the endogenous β-promoter (Brown et al., 2002).  
 
Based on prior structural analysis of EKLF, the activation domain of EKLF 
should reside in sequences upstream of the Δ221-253 regions.  Our hypersensitive studies 
suggested that the transcriptional and chromatin remodeling domain activities of EKLF 
are separable.  To test this hypothesis, transcriptional activity for each mutant was 
measured by RNA protection assay and correlated with its chromatin remodeling 
properties (Figure 1.3C).  As anticipated, no significant level of the βmaj transcript was 
detected in Δ253EKLF cells.  In contrast, expression of the Δ221EKLF polypeptide 
resulted in a small increase in gene transcripts.  However, examination of cells expressing 
Δ164EKLF revealed levels of βmaj transcripts that paralleled flEKLF expression.  Thus,  
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Figure 1.3. Separable chromatin remodeling and transactivation domains of EKLF. 
(A) Schematic diagram of flEKLF retrovirus and derivative mutants used to stably 
transduce J2e eklf cells. (B) The DNA binding domain (Δ253) is required but is not 
sufficient for chromatin remodeling at the ßmaj globin promoter. Cells expressing each 
EKLF mutant were cultured for 48 h in the presence of tamoxifen. Nuclei were isolated 
and exposed to increasing concentrations of DNase I as previously described. DNA was 
harvested, digested with EcoRI, and probed with a ßmaj-specific probe. The DNase I 
concentration is 0 in the first lane of each panel and increases as shown by the shaded 
triangle. (C) An internal domain of EKLF (Δ164) is sufficient to activate ß-globin gene 
expression to wild-type levels. RNA was harvested from J2e eklf clones expressing 
varying EKLF mutant moieties at 48 h post-tamoxifen induction RPA was performed 
utilizing ßmaj and riboprobes. The numbers underneath the panel represent the mean fold 
induction of the ß/α  ratio for each construct assayed.  Amended with permission from 
American Society for Microbiology. Brown, R. C., S. Pattison, R. J. van Ree, E. Coghill, 
A. Perkins, S. M. Jane, and J. M. Cunningham. 2002. Distinct domains of erythroid 
Krüppel-like factor modulate chromatin remodeling and transactivation at the 
endogenous beta-globin gene promoter. Mol. Cell. Biol. 22:161-170/DOI:10.1128. 
an internal domain of EKLF is sufficient to activate β-globin gene expression to wild-
type levels (Brown et al., 2002).  These observations are contrasted with previous studies 
in which the first 104 amino acids of EKLF activated GAL4-dependent transcription 
(Chen & Bieker, 1996).  More importantly, our studies indicate EKLF contains separable 
chromatin remodeling and transactivation domains. 
 
 
PROJECT OUTLINE 
  
I joined Dr. Cunningham’s laboratory with a strong interest in studying globin 
gene regulation to understand the molecular mechanism underlying one of the most 
common hematological disorders, β-thalassemia.  Success in this endeavor would 
identify therapeutic targets that would reverse or delay the globin gene switch, thus 
ameliorating the β-thalassemic or sickle cell disease phenotype.   
 
Based on the cellular studies by previous colleagues in the laboratory, I propose to 
examine the role of the newly defined chromatin remodeling domain of EKLF 
(∆221EKLF) in a whole animal model that allows the analysis of modulation of gene 
expression and chromatin structure.   My working hypothesis is that expression of the 
chromatin remodeling domain of EKLF, in the absence of the transactivation domain, is 
necessary and sufficient for altering the chromatin structure at the β-globin locus in vivo.  
A corollary hypothesis is that expression of the chromatin remodeling domain alone is 
not sufficient for activation of β-globin gene transcription in vivo.  I plan to generate 
specific mutants of the EKLF gene at the endogenous locus in a murine knock-in model 
to address the following specific aims. 
 
 
Specific aim 1: To characterize the cellular consequences on murine hematopoiesis of 
expression of the knock-in allele in vivo. 
 
The goal of this specific aim is to provide an initial analysis of the cellular effects 
of ∆221EKLF expression in a murine model.  First, matings between Δ221EKLF 
heterozygous male and female animals will be established to determine if Δ221EKLF 
homozygous animals are viable.  If no adult Δ221EKLF homozygous animals are 
observed, I will dissect embryos at different time points during gestation to determine 
when and how Δ221EKLF animals die.  I hypothesize that animals expressing 
∆221EKLF die of a lethal anemia similar to the EKLF knock-out mice.  Similarly, I 
predict that cells expressing ∆221EKLF fail to execute normal terminal differentiation. 
These studies should provide valuable information on the role of the chromatin 
remodeling domain of EKLF in transactivation of β-globin gene transcription in vivo. 
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Specific aim 2: To evaluate the functional consequences of expression of the knock-in 
allele on EKLF-dependent erythroid gene transcription. 
 
I propose to explore the effects of ∆221EKLF expression on gene transcription in 
vivo.  Utilizing real time RT-PCR, I will quantify the transcription of the β-globin gene 
and putative non-β-globin EKLF-target genes to determine whether any of these genes 
require the chromatin remodeling properties of EKLF alone for gene transcription.  Based 
upon our laboratory’s cellular studies, my overarching hypothesis is that expression of 
the chromatin remodeling domain in the absence of the transactivation domain is not 
sufficient to activate gene transcription. Together, these results will provide insights into 
the role of EKLF in coordinating gene transcription at the β-globin locus and other gene 
loci. 
 
 
Specific aim 3: To explore the functional consequences of expression of the knock-in 
allele on chromatin structure at the β-globin locus. 
 
The studies proposed in this aim will directly test my working hypothesis that 
expression of ∆221EKLF is sufficient for altering chromatin structure at the β-globin 
locus.  First, I will analyze the nucleosomal remodeling of the β-globin promoter as 
measured by DNase I hypersensitivity.  Subsequently, I will investigate the histone 
acetylation and methylation patterns at the β-globin locus utilizing quantitative chromatin 
immunoprecipitation (ChIP).  The proposed studies should corroborate the observations 
in our EKLF-dependent erythroblast model and provide insight into the role of chromatin 
remodeling in transactivation of β-globin gene transcription.   
 
In this dissertation, I describe the generation of the knock-in alleles of EKLF and 
the consequences of expression of the Δ221EKLF in erythroid and megakaryocytic 
differentiation.  In Chapter 2, I will describe the construction of gene targeting vectors 
utilizing recombineering technology and the generation of Δ221EKLF heterozygous 
animals.  In Chapter 3, I will report on the molecular consequences of expression of 
Δ221EKLF as it relates to chromatin remodeling and transcriptional activation of β-
globin.  In Chapter 4, I will report on the novel role for EKLF in megakaryocytic 
differentiation. 
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CHAPTER 2: GENERATION OF A KNOCK-IN ALLELE OF EKLF UTLIZING 
RECOMBINEERING TECHNOLOGY 
 
 
INTRODUCTION 
 
Genetically engineered mouse models have proven to be useful tools for many 
applications in research, medicine, and biotechnology.  The approaches to generating 
these different mouse models have traditionally been based on the over-expression or 
ablation of a gene using transgenic and knock-out strategies, respectively (Roebroek et al., 
2002).  More recently, by using a knock-in approach and placing the expression of an 
exogenous gene under the transcriptional control of cis-acting elements belonging to the 
endogenous gene, investigators are able to study the gene in a more subtle manner 
(Roebroek et al., 2002).   
 
Methods used for genetic engineering have relied mostly on a conventional 
approach.  Restriction enzymes and DNA ligases are used to clone an appropriate piece 
of DNA sequences into a targeting vector.  The major limitation of this strategy is the 
difficulty and time it takes to generate this vector utilizing large fragments of DNA 
(Copeland et al., 2001; Liu et al., 2003).  At the time that I initiated my dissertation 
studies, a new and highly efficient method for manipulating the mouse genome had been 
developed.  Termed recombineering, this method relies on the lambda phage-based 
homologous recombination in Escherichia coli to construct the targeting vector (Yu et al., 
2000; Liu et al., 2003). Using this technology, it is possible to introduce large double-
stranded DNA (dsDNA) fragments into DNA cloned on plasmids, bacterial artificial 
chromosomes (BACs), or P1 artificial chromosomes (PACs) via homologous 
recombination without the need for restriction enzymes or DNA ligases (Copeland et al., 
2001;  Liu et al., 2003).  Additional advantages of using this new technology are speed, 
efficiency, and reliability. 
 
Originally, recombineering has been utilized in yeast due to its efficient DNA 
double-stranded-break-and-repair recombination pathway, allowing the creation of 
recombinant DNA molecules by homologous recombination (Baudin et al., 1993).  These 
recombination pathways allow efficient recombination of transformed linear, double-
stranded DNA (dsDNA) with homologous sites in the yeast genome.  Moreover, 
proficient recombination occurs even with only short stretches of homologous sequence, 
thereby allowing recombinant DNA to be generated in vivo without the use of restriction 
enzymes and DNA ligases (Baudin et al., 1993).   Unlike in yeast, dsDNA is unstable in 
E.  coli due to the presence of RecBCD, an ATP-dependent exonuclease that degrades 
dsDNA.  However, E. coli strains that lack RecBCD can be transformed by linear dsDNA 
(Baudin et al., 1993).   
 
There are disadvantages to utilizing yeast and yeast artificial chromosomes 
(YACs) in recombineering.  First, YACs are less stable in their yeast host, in which 
recombination is potent and always active.  Thus, undesired deletions and gene 
rearrangements are a barrier to using this organism.  In contrast, bacterial artificial 
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chromosomes (BACs) are stable in E. coli (Shizuya et al., 1992; Copeland et al., 2001). 
Moreover, YAC DNA is more difficult to purify compared to BAC DNA (Copeland et al., 
2001).  A yeast cell may contain both wild-type and modified YACs (Peterson et al., 
1997), whereas a bacterial cell typically contains a single BAC (Copeland et al., 2001).  
Finally, manipulating recombinant YACs that are generated in yeast can be laborious and 
usually requires the YACs to be transferred to E. coli for subsequent manipulation, 
whereas BAC modification occurs directly in E. coli (Copeland et al., 2001). 
 
Recombineering in E. coli can be accomplished by making use of lambda phage's 
homologous recombination proteins, called Red, which allow linear dsDNA fragments to 
be inserted via homologous recombination into DNA cloned on plasmids (Yu et al., 
2000; Cotta-de-Almeida et al., 2003; Zhang & Huang, 2003). To generate a 
recombinogenic strain of bacteria, a defective lambda prophage which lacks lysis and 
replication functions but retains the Red proteins is inserted into the bacterial genome 
(Yu et al., 2000). The phage genes of interest, exo, bet, and gam, are transcribed from the 
λPL promoter. This promoter is repressed by the temperature-sensitive repressor cI857 at 
32°C.  In contrast, derepression, that is the repressor is inactive, occurs at 42°C (Yu et al., 
2000).  At low temperatures (i.e., 32°C) no recombination proteins are produced.  
However, following a temperature shift to 42oC for as little as 15 min, these proteins are 
expressed at high levels.  The 5'-3' exonuclease, exo, creates single-stranded overhangs 
on introduced linear DNA; bet protects these overhangs and assists in the subsequent 
recombination process.  Degradation of linear DNA is protected by gam, which inhibits 
the E. coli RecBCD protein (Yu et al., 2000).   
 
Following induction of the recombination genes, linear dsDNA such as PCR 
products and oligonucleotides with sufficient homology in the 5' and 3' ends to a target 
DNA molecule already present in the bacteria (plasmid, BAC, or the bacterial genome 
itself) can be introduced into heat-shocked and electrocompetent bacteria using 
electroporation. The introduced DNA is modified by exo and bet and undergoes 
homologous recombination with the target molecule. The method is so efficient that co-
electroporation of a supercoiled plasmid and a linear piece of DNA into heat-shocked, 
electrocompetent bacteria will work as well (Yu et al., 2000; Copeland et al., 2001; Liu 
et al., 2003).  
 
This chapter describes the generation of knock-in mutant alleles of EKLF using 
the recent recombineering technology that encompasses a phage-based E. coli 
homologous recombination system.  Several groups have used this new form of genetic 
engineering to construct standard, conditional, and knock in gene targeting vectors to 
modify murine embryonic stem (ES) cells (Lui et al., 2003; Zhou et al., 2004).  Utilizing 
this method, I have constructed three targeting vectors in which cDNA encoding three 
different truncation mutations of EKLF (Δ164EKLF, Δ221EKLF, and Δ253EKLF) have 
been inserted into the endogenous murine EKLF locus.  The construction of all three 
targeting vectors was completed without the constraints of restriction sites and took a 
shorter time than a similar strategy utilizing traditional subcloning methods.  
Subsequently, the targeting vectors were used to target the endogenous murine EKLF 
locus in ES cells.  The animals I have generated should prove to be useful tools for 
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analyzing the distinct molecular functions of EKLF in vivo. 
 
Based upon recommendations from my graduate committee, I have chosen to 
focus my dissertation studies on characterizing one strain of mice while the other two 
strains are studied by my colleagues in the laboratory.   I have chosen to focus on the 
Δ221EKLF strain for several reasons.  First, previous studies by my laboratory colleagues 
have demonstrated that the Δ221EKLF domain is sufficient to alter local chromatin 
structure at the endogenous β-globin promoter; however this domain alone is insufficient 
to transactivate β-globin gene transcription to wild-type levels in a cellular model. Thus, 
the strain of mice expressing Δ221EKLF is the most ideal model to elucidate the role of 
EKLF in chromatin remodeling and gene activation in vivo.  
 
 
MATERIALS AND METHODS 
 
 
BAC transfer into recombinogenic strains 
 
An EKLF BAC clone in DH10B was obtained from the BACPAC Resources 
Center at Children’s Research Hospital Oakland Research Institute (CHORI).  The EKLF 
BAC DNA (75kb) was purified using the Miniprep DNA kit (Qiagen) as previously 
described (Liu et al., 2003).  Briefly, E. coli cells encoding BACs were grown overnight 
in LB broth (5 mL) with chloramphenicol. Cells were collected by centrifugation at 
maximum speed (12,000 x g or 13, 000 rpm) and resuspended in buffer P1 (250 µL).  
Buffer P2 (250 µL)  and buffer P3 (350 µL) were added to each tube, and the tubes were 
spun for 4 min at 12,000 x g. The supernatant was transferred to a new 1.5 mL tube and 
cleared by centrifugation for another 4 min.  Isopropanol (750 µL) was added to the 
mixture, and DNA was precipitated  at room temperature for 10 min.  The DNA was 
collected by spinning the tube for 10 min at the maximal speed, washed once with 70% 
ethanol (1.0 mL), air dried, and resuspended in TE (50 µL).  The purified EKLF BAC 
DNA (100-200 ng) was electroporated into the recombinogenic E. coli strain EL350 (a 
kind gift from Dr. Neal Copeland) using a BIO-RAD electroporator at 1.75 kV, 25 µF 
with the pulse controller set to 200 Ω and time constant between 4.3-4.7. Transformed 
colonies were recovered on LB agar with 40 μg/mL chloramphenicol.  The EKLF BAC 
DNA prepared from the original DH10B and transformed EL350 bacteria was digested 
with BamHI, EcoRI, and HindIII and separated on agarose gels to confirm that no DNA 
rearrangements had occurred during the BAC transfer. 
 
 
Plasmids 
 
The EKLF BAC retrieval plasmid was generated by ligating PCR product AB 
(left arm, EcoRI/BamHI), PCR product XY (right arm, BamHI/XbaI), and MC1-TK/polII-
DT (VP101, EcoRI/XbaI) using T4 DNA ligase (Promega).  The mini-targeting plasmid 
was generated in two-steps.  First, PCR product EF (BglII/NotI) was ligated with a floxed 
Neo-containing vector, a kind gift from Dr. Neal Copeland (PL452, BamHI/NotI).  Then 
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PCR product CD (SalI/HindIII) and HA-∆221EKLF cDNA-containing fragment (pspHA-
EKLF-C3, HindIII/EcoRI) were ligated with the vector containing the Neo cassette and 
PCR product EF generated in the first step.  The ligation product was transformed into 
chemically competent DH5α cells (Invitrogen) and plated on selective media containing 
both kanamycin (50 μg/mL) and carbenicillin (100 μg/mL).  Only bacterial cells 
propagating the subcloned vector with the Amp and Neo resistance genes should grow 
under these conditions. 
 
 PCR products were amplified using ROCHE Expand High-Fidelity PCR System 
using 50 ng of BAC DNA following the manufacturer’s recommendations. PCR was 
performed using an MJ Research PCR machine with the following settings: 94°C for 2 
min, then 10 cycles of 94°C for 15 sec, 55°C for 30 sec, and 72°C for 45 sec. This was 
followed by 15 cycles of 94°C for 15 sec, 55°C for 30 sec, 72°C for 45 sec, with an 
additional 5 sec extension time each cycle. To check the PCR reaction, 5 µL of the 50 µL 
PCR reaction mixture was loaded onto an agarose gel. The remaining 45 µL of PCR 
product was purified using the QIAGEN PCR Purification Kit. 
 
 
Recombineering 
 
Recombineering was performed as previously described (Liu et al., 2003).  To 
retrieve the gap-repaired plasmid, EL350 cells containing the EKLF BAC was grown at 
32oC to an OD600 = 0.5 in LB broth with chloramphenicol.  The cells were transferred to 
and shaken in a 42oC water bath for 15 min to induce expression of the λ recombination 
proteins, and quickly chilled in ice water for 10 min.  Electrocompetent cells were 
prepared by washing the cells three times with ice cold water.  Finally, the cell pellet was 
resuspended in ice cold water (50 µL) and electroporated with the BamHI-linearized 
retrieval vector (1-2 µL).  After electroporation, 1 mL of LB medium was added to the 
cuvette, and the culture was incubated at 32oC for 1 h with shaking.  The cells were then 
plated on agar plates with the appropriate antibiotic. 
 
For targeting, frozen EL350 electrocompetent cells previously prepared in the 
laboratory were used.  The frozen cells were thawed at room temperature and quickly put 
on ice.  These cells were co-electroporated with the targeting cassette (100 ng) and the 
gap-repaired plasmid (10 ng) DNA as previously described (Liu et al., 2001).  The 
targeting cassette was excised from the mini-targeting vector with NotI and SalI digest 
and purified by the QIAGEN Gel Purification System. 
 
 
Excision of the Neo cassette in bacteria 
 
Frozen EL350 cells previously prepared in the laboratory and induced for Cre 
expression by prior growth in arabinose-containing medium were used to test the excision 
of the floxed Neo cassette.  The EL350 strain of E. coli was previously engineered to 
harbor an arabinose-inducible Cre gene (PBAD-cre) (Lee et al., 2001; Liu et al., 2003). 
Plasmid DNA (10-50 ng) was electroporated into frozen electrocompetent cells (50 µL).  
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LB medium (1 mL) was added to the cuvette, and the culture was shaken at 32oC for 1 h.  
The cells were plated on ampicillin-containing media.  DNA was extracted from selected 
ampicillin-resistant colonies and digested with restriction enzymes. 
 
 
Gene targeting in ES cells and generation of Δ221EKLF mice 
 
 ES cells were obtained from Specialty Media and maintained following the 
manufacturer’s recommendations. For gene targeting, the NotI linearized HA-
∆221EKLF-KI construct was electroporated into 129Sv ES cells (Specialty Media) and 
recombinants were selected in medium supplemented with G418 (Gibco) and ganciclovir 
(Syntex).  Selection was continued for eight days and the surviving ES clones were 
picked and expanded for an additional four days.  Genomic DNA was extracted from 
each clone and analyzed by Southern blotting to identify properly targeted ES clones.  
Sequences for 5’ and 3’ probes used in Southern blot analysis are available in Appendix 
Figure A.2. 
 
Properly targeted ES clones with a normal karyotype were injected into C57BL/6 
blastocysts and transferred into pseudopregnant females to generate chimeras (Transgenic 
Core Facility at St. Jude Children’s Research Hospital).  Male chimeras were mated with 
C57BL/6 wild-type females to generate F1 offsprings.  To remove the floxed Neo 
cassette, ∆221EKLF heterozygous mice were mated with mice harboring the cre 
transgene diallelically expressed under the control of the adenovirus EIIa promoter that 
targets expression of Cre recombinase to the early mouse embryo (Jackson Labs).  
 
 
Mouse genotyping 
 
For Southern blotting, mouse tail DNA was digested with NheI (New England 
Biolabs), separated on 0.8% agarose gels, and transferred to GeneScreen Plus 
hybridization transfer membrane (Perkin Elmer). A 543 bp 3' external probe was used for 
hybridization. Genotyping by PCR was performed using a common WT and KI forward 
primer, (5’-ATGAGGCAGAAGAGAGAGAGGAG-3’), a WT reverse primer (96 bp; 5’-
TGAGTGTACTGATGGAGGGTAAGA-3’), and a KI reverse primer (500 bp; 5’-
CCGTGTGTTTCCGGTAGTG-3’).  PCR primers for genotyping were designed using 
Primer Design in Clone Manager.  PCR was performed on a BIORAD PCR machine with 
the following settings: 94oC for 3 min followed by 32 cycles of 94oC for 30 sec, 60oC for 
30 sec, and 72oC for 1 min with a final extension at 72oC for 10 min.  Products were 
visualized on agarose gel with ethidium bromide staining. 
 
 
Husbandry of mice 
  
The animals used in the studies were housed in the Animal Resources Center of St 
Jude Children’s Research Hospital, Memphis, Tennessee, and the University of Chicago, 
Chicago, Illinois, according to approved Animal Care Use Protocols (ACUP). 
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Analysis of peripheral blood counts 
 
Blood was harvested from the retro-orbital sinus into EDTA-coated 
microcapillary tubes and submitted to the St Jude Children’s Research Hospital Animal 
Diagnostic Laboratory for complete blood count (CBC) analysis including a peripheral 
blood smear. 
 
 
Primers  
 
PCR primers for recombineering were designed using Primer Design in Clone 
Manager or Primer 3.  The primer sequences used for generating the HA-∆221EKLF-KI 
targeting vector are:  
AB-fragment (540 bp): Primer A: 5’-CGGAATTCGGTGCTGGTGGTTGTCTAGG-3’ 
Primer B: 5’-CGCGGATCCTGTGGTTGCTTGTAATTGA-3’;  
XY-fragment (640 bp): Primer X: 5’-CGCGGATCCTACATAGCCTCTGTGCATTC-3’; 
Primer Y: 5’-GCTCTAGACACCGTCTCTAGGTCAGGTA-3’; CD-fragment (596 bp): 
Primer C: 5’-ACGCGTCGACCAAAGGGTCCCAAAGACCTTTC-3’; Primer D: 5’-
GGGTGGTGAGTGTACTGATG-3’; EF-fragment (541 bp): Primer E: 5’-
GGAAGATCTGGCAGGTGGTCTTGCATAGG-3’; Primer F: 5’-
ATAAGCGGCCGCAGTATTCAGGATGGGAGAAG-3’;  Primers used to generate the 
fragment containing the HA-Δ221EKLF sequence were Forward: 5’-
CATGCCATGGCCTATGACGTCCCAGATTACG-3’; Reverse: 5’-
AGTCAGGATATCCTACTTAGTCAAAGGTGGCGCTTCATGTGC-3’. 
 
 
RESULTS 
 
 
Generation and characterization of targeting vectors 
 
To elucidate the role of the functional domains of EKLF in primary mouse 
erythroblasts, I proposed to generate animals expressing distinct domains of EKLF 
identified in previous cellular assays (Brown et al., 2002).  Targeting vectors, in which 
cDNA encoding HA-tagged truncation mutant of EKLF linked in cis to a Neo selection 
cassette (HA-Δ221EKLF-Neo) were generated, utilizing recombineering methods. The 
overall strategy is illustrated in Figure 2.1.   
  
First, to facilitate the manipulation of the EKLF genomic locus by recombineering, 
it was necessary to retrieve a region of the mouse genome containing the EKLF gene and 
its cis-regulatory sequences. To accomplish this, a vector capable of retrieving an 11 kb 
fragment spanning the EKLF locus was constructed by subcloning PCR amplified 
fragments AB and XY into an expression vector. These regions, AB and XY, mark the 5’ 
and 3’ ends of the fragment to be subcloned by gap repair, respectively.  Next, to obtain 
the gap-repaired plasmid containing our genomic region of interest (Figure 2.2A), the 
BamHI-linearized retrieval vector was electroporated into the recombinogenic bacterial  
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Figure 2.1. Overview of the recombineering method used to generate vectors for 
targeting in ES cell.  A BAC clone containing the EKLF genomic locus was transferred 
from the E. coli strain DH10B to the recombinogenic strain EL350.  These cells were 
electroporated with a BamHI linearized retrieval plasmid containing PCR products, AB 
and XY, of homology to the EKLF BAC.  By gap-repair, this plasmid rescued an 11 kb 
fragment containing the EKLF gene plus 3 kb of upstream sequences and 4.5 kb of 
downstream sequences.  Cells containing the correct gap-repaired plasmid were 
electroporated with a fragment containing HA-Δ221EKLF-floxed Neo flanked by 
homology sequence from the EKLF genomic locus.  This fragment was excised from the 
mini-targeting vector in which PCR products CD, EF, and HA-Δ221EKLF were 
subcloned into the PL452 plasmid containing a floxed Neo cassette. The resulting 
plasmid containing the modified EKLF locus with insertion of HA-Δ221EKLF-floxed 
NEO cassette into the ATG at amino acid 19 was linearized with NotI and electroporated 
into ES cells.  EKLF contains three exons (E1-E3) as denoted by black boxes.  AB 
(green) and XY (blue) are homologous to a region upstream and downstream of the 
EKLF locus, respectively.  CD (red) and EF (orange) flank the fragment to be 
recombineered into the EKLF locus and are homologous to sequences in exon 1 of the 
EKLF gene.  The CD region, containing the ATG start site, is placed in frame with HA-
Δ221EKLF encoding sequences. Lox P sites are represented by black arrow heads. 
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Figure 2.2. Mapping of the gap-repaired plasmid.  (A) Diagram of the resultant gap-
repaired plasmid obtained by electroporation of EL350 cells harboring EKLF BAC with a 
BamHI-linearized retrieval vector. DT = diphtheria toxin; TK = tymidine kinase; Amp = 
Ampicillin (B) To confirm the capture of the 11 kb EKLF BAC with appropriate flanking 
sequences, DNA was isolated from 18 colonies and digested with XhoI (10 kb and 7 kb).  
(C) Subsequently, DNA from 4 colonies (indicated by arrows from above) was digested 
with NotI/SpeI (9.4 kb, 7.7 kb), XbaI (6.8kb, 6.3 kb, 4.0 kb) and HindII (7.0 kb, 6.0 kb, 
4.0 kb), respectively.  The expected bands are in parentheses. 
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 strain harboring the EKLF BAC.  Since these bacterial cells had been engineered to 
express the λ recombination system with induction at 42oC, homologous recombination 
would occur resulting in the retrieval of the mouse genomic region flanked by the 
homology arms AB and XY.  DNA from 18 ampicillin-resistant colonies were purified 
by the miniprep method and digested with XhoI to identify homologous recombinants.  
As shown in Figure 2.2B, DNA from 17 out of 18 colonies digested with XhoI showed 
the predicted 7 kb and 10 kb bands.  The DNA in lane 4 appears to be undigested plasmid 
containing at least two topologically different forms of DNA, corresponding to 
supercoiled forms (bottom band) and nicked circles (upper band).  DNA from four 
colonies (indicated by arrows) was selected for further restriction enzyme analysis.  
Digest with NotI/SpeI (9.4 kb / 7.7 kb), Xba1(7.0 kb / 6.0 kb / 4.0 kb), and HindIII (7.0 
kb / 6.0 kb / 4.0 kb) produced fragments of the expected sizes (Figure 2.2C).  Four DNA 
samples confirmed by restriction mapping were sent for sequencing at the Hartwell 
Center of St Jude Children’s Research Hospital.  One construct had numerous mutations 
and deletions near the junctions where homologous recombination took place while 
another construct had base pair substitutions within the EKLF gene.  The gap-repaired 
plasmid with the correct sequences was selected for the next step in recombineering. 
 
Next, a mini-targeting vector containing the knock-in fragment that will be used 
to target the gap-repaired plasmid was constructed by subcloning.  Fragment EF which is 
homologous to the targeting site was generated by PCR, digested with BglII/NotI, and 
ligated with PL452 DNA digested with NotI/BamHI.  The restriction enzymes BglII and 
BamHI have compatible ends (New England Biolabs).  The floxed Neo gene in PL452 is 
expressed from a hybrid PGK-EM7 promoter (Liu et al., 2003). Expression of Neo from 
the PGK promoter permits selection of Neo resistant mammalian ES clones.  On the other 
hand, EM7 drives Neo expression in bacterial cells facilitating selection of Neo resistant 
colonies.  PCR was used to generate the CD fragment with SalI and HindIII sites and a 
fragment containing HA-∆221EKLF sequences with stop codons in all three reading 
frames and addition of HindIII and EcoRI restriction sites.  Homology arm CD was 
designed carefully so that the HA-∆221EKLF cDNA would be inserted into the 
endogenous ATG start site, placing the mutant gene under the cis-regulatory control of 
the endogenous locus.  
 
To complete subcloning the mini-targeting vector (Figure 2.3A), SalI/HindIII-
digested CD fragment and HindIII/EcoRI-digested HA-∆221EKLF fragment were ligated 
with SalI/EcoRI-digested PL452-EF plasmid DNA.  The ligation product was 
transformed into DH5α competent cells and plated on kanamycin/ampicillin selective 
media.  Colonies propagating the subcloned plasmid with the Amp and Neo resistant 
genes should only grow under these conditions.  Restriction analysis with EcoRI digest 
identified six out of eighteen colonies that were homologous recombinants (Figure 2.3B, 
as indicated by arrows).  DNA from these six colonies was subjected to further restriction 
digestion analysis with NotI/SalI (3.5 kb, 2.9 kb), NheI (5.8 kb, 0.6 kb), XhoI (3.4 kb, 3.0 
kb), and HindIII/EcoRI (3.7 kb, 2.2 kb, 0.6 kb) (Figure 2.3C).  Three of the six colonies 
showed the correct restriction patterns.  Before proceeding with the final step, the mini-
targeting vector was extensively analyzed by restriction enzyme digestion (Appendix 
Figure A.1; Table A.2). Furthermore, sequence analysis of the junctions between CD- 
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Figure 2.3.  Analysis of Δ221EKLF mini-targeting vector.  (A) Plasmid map of HA-
Δ221EKLF mini targeting vector with restriction enzyme sites. CD, EF = homologies to 
EKLF gene; Amp = Ampicillin; Neo = Neomycin (B) DNA from 18 kanamycin resistant 
colonies were prepared and digested with EcoRI (4.3 kb, 2.2 kb). (C) DNA from the six 
correctly identified colonies (in lanes 1, 2, 3, 5, 7, and 11 panel B) was further digested 
with NotI/SalI (3.5 kb, 2.9 kb), NheI (5.8 kb, 0.6 kb), XhoI (3.4 kb, 3.0 kb), and 
HindIII/EcoRI (3.7 kb, 2.2 kb, 0.6 kb), respectively.  The predicted fragments for the 
correctly targeted vector are in parentheses 
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HA-Δ221EKLF-Neo-EF confirmed that the predicted sequence was present.   
 
 Finally, to obtain the final targeting vector (Figure 2.4A) that will be used for 
targeting in ES cells, the complete mini-targeting cassette was introduced into the gap-
repaired plasmid by recombineering.  The mini-targeting cassette containing CD-HA-
Δ221EKLF-Neo-EF was first excised from PL452 by NotI/SalI digest and gel-purified.  
Then, the purified cassette (300 ng) was co-electroporated along with the gap-repaired 
plasmid DNA (50 ng) into EL350 cells, which had been induced for Red recombination 
at 42oC.  Subsequently, the bacterial cells were plated on ampicillin/kanamycin selective 
media.  No growth was visible after 24-48 hr incubation at 32oC.  Co-electroporation was 
then attempted with varying amounts of targeting cassette (100-500 ng) and gap-repaired 
DNA (10-100 ng).  Several ampicillin/kanamycin-resistant colonies were analyzed, 
however, there were no correct recombinants.  I then decided to perform sequential 
electroporation.  First, the gap-repaired DNA was electroporated into EL350 cells.  The 
colonies were selected and the DNA digested with restriction enzymes to identify the 
bacterial colony containing the gap-repaired plasmid.  Next, the mini-targeting cassette 
was electroporated into EL350 cells containing the gap-repaired plasmid.  These cells had 
been induced for the Red recombination genes by a short incubation at 42oC to allow 
homologous recombination to occur.  This resulted in modification of the EKLF genomic 
locus contained in the gap-repaired plasmid by targeting the mini-cassette to the start site 
of EKLF. 
 
Prior to gene targeting in ES cells, the final targeting vector was characterized 
structurally and functionally.  First, to screen for aberrant gene rearrangements, DNA 
from the gap-repaired plasmid (denoted 1), Δ164EKLF targeting vector (denoted 2), 
Δ221EKLF targeting vector (denoted 3), and Δ253EKLF targeting vector (denoted 4) 
were digested with numerous restriction enzymes.  Shown in Figure 2.4A are the 
restriction enzyme patterns after digestion with EcoRI, HindIII, XhoI, XbaI, AccIII, KpnI, 
SpeI, and PvuI, respectively.  All samples displayed the expected digestion pattern by 
agarose gel electrophoresis.  The predicted fragments are listed in Table 2.1.  Next, to 
evaluate for mutations that may have occurred during recombineering, DNA from each 
targeting vector was submitted to the Hartwell Center at St Jude Children’s Research 
Hospital for sequence analysis and confirmed that the targeting vectors had the correct 
sequences. 
 
Finally, to ensure that the loxP sites in the targeting vectors would properly 
recombine in the presence of cre recombinase thereby removing the Neo cassette, the 
targeting vectors were electroporated into EL350 cells, which had been induced for cre 
expression by prior growth in arabinose-containing medium.  Ampillicin-resistant 
colonies were picked and the DNA from these colonies was digested with SpeI, HindIII, 
BamHI, and NheI, respectively (Figure 2.4B, data shown for Δ221EKLF only).  After cre 
induction, there is a loss of SpeI and NheI sites resulting in only one band.  Digestion 
with HindIII and BamHI leads to a smaller product due to excision of the Neo  
cassette as demonstrated by one of the bands being shifted lower (i.e., lower molecular 
weight). 
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Figure 2.4. Verification of the final targeting vector using restriction enzyme 
analysis. (A)  Plasmid map of the HA-Δ221EKLF final targeting vector. DNA was 
prepared from ampicillin/kanamycin-resistant colonies and subjected to digestion with 
various enzymes. Lane 1 = retrieval vector containing 11 kb EKLF BAC; lane 2 = HA-
∆164EKLF; lane 3 = HA-∆221EKLF; lane 4 = HA-∆153EKLF. (B) Plasmid maps of the 
HA-Δ221EKLF final targeting vector with and without Neo. The final targeting vector 
was electroporated in EL350 cells induced for cre expression and ampicillin-resistant 
colonies were picked.  DNA from the colonies was digested with several restriction 
enzymes. CD, EF = EKLF homologies; DT = diphtheria toxin; TK = thymidine kinase; 
Amp = Ampicillin; Neo = Neomycin. 
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Enzyme Retrieval (1)        Δ164 (2)        Δ221 (3)        Δ253 (4) 
       plasmid 
 
EcoRI   9.5  9.6  9.5  9.4 
    3.4  4.0  3.8  3.7 
      2.1  2.1  2.1  
 
HindIII  7.0  9.6  9.5  9.4 
    5.9  5.9  5.9  5.9 
  
XhoI   7.3  7.9  7.7  7.6 
    5.8  5.8  5.8  5.8 
      1.8  1.8  1.8 
  
XbaI   7.3  8.9  8.9  8.9 
    5.6  4.8  4.6  4.5 
      1.9  1.9  1.9 
 
AccIII   8.0  8.0  8.0  8.0  
    4.9  5.5  5.4  5.3 
      2.0  2.0  2.0 
 
KpnI   7.1  7.1  7.1  7.1 
    4.0  4.0  4.3  4.2 
    1.8  3.0  4.0  4.0 
      1.4 
   
SpeI   12.9  12.8  12.8  12.8 
        2.7    2.6    2.5 
 
PvuI   6.6  9.3  9.1  9.0 
    5.2  5.2  5.2  5.2 
    1.0  1.0  1.0  1.0 
 
     
Table 2.1. Predicted fragment size with restriction enzyme digestion. 
Targeting of the murine EKLF genomic locus 
 
A targeting vector was generated to introduce the Δ221EKLF encoding cDNA at 
the start ATG of the endogenous EKLF gene (Figure 2.5A).  EKLF has only 3 exons 
(Miller & Bieker, 1993).  In my targeting strategy, exons 2 and 3 of the endogenous gene 
were left intact.  Stop codons were placed in all three reading frames to ensure proper 
translation of the knock-in allele.  The 5’ and 3’ homology regions were 3 kb and 4 kb, 
respectively.  MC1-thymidine kinase and PolII-diptheria toxin cassettes were included 
for double negative selection in the ES cells.  This selection strategy has been 
successfully utilized in our laboratory to enrich for ES clones that have undergone 
homologous recombination, as opposed to random integration (V.P. personal 
communication).  The data shown here are specific to HA-Δ221EKLF, however, 
targeting for HA-Δ164EKLF and HA-Δ253EKLF were completed in a similar fashion.    
 
To replace the wild-type EKLF gene with HA-Δ221EKLF in ES cells, the 
targeting vector was linearized by NotI digestion and electroporated into 129/SvEv ES 
cells.  After eight days of selection in G418 and ganciclovir, ES cell clones were picked 
and expanded.  Genomic DNA from these clones was digested with EcoRV or NheI and 
analyzed by Southern blot analysis with 5’ and 3’ probes, respectively. The wild-type 
EKLF allele is detected as an 8.7 kb fragment with the 5’ probe and as an 11.1 kb 
fragment with the 3’ probe.  The recombinant allele is detected as a 9.1 kb fragment with 
the 5’ probe and as a 6.8 kb fragment with the 3’ probe because of the introduction of 
novel EcoRV and NheI sites into the 5’ and 3’ regions of the genes, respectively, in the 
targeting vector.  As shown in Figure 2.5B, ES DNA in lanes 3-7 of the top panel contain 
the 8.7 kb wild-type allele and the 6.8 kb knock-in allele with the 5’ probe, whereas lanes 
1-2 are wild-type ES cell DNA containing only an 8.7 kb fragment.  Similarly, ES cell 
DNA in lanes 3-6 of the bottom panel contain the 11.1 kb wild-type allele and the 9.1 kb 
knock-in allele with the 3’ probe, and lanes 1-2 are wild-type ES cell DNA containing 
only an 11.1 kb fragment.  A total of 223 ES clones were screened, and 17 positive clones 
were identified (~ 8% recombinants). 
 
 
Δ221EKLF heterozygous mice are phenotypically normal 
 
ES cells properly targeted with Δ221EKLF were injected into C57Bl/6 wild-type 
blastocysts to generate Δ221EKLF chimeras.  Male chimeras whose genetic composition 
is derived from the ES cells and donor blastocysts were mated with female C57Bl/6 mice 
to transmit the knock-in allele.  To remove the Neo cassette, F1 offspring were then 
crossed with mice harboring a cre transgene under the control of the adenovirus EIIa 
promoter that targets the expression of cre recombinase to the early mouse embryo 
(Jackson Laboratory).  Our studies utilized mice in which the Neo cassette has been 
removed, thereby eliminating the possibility of Neo gene expression interfering with our 
observed results.  To identify animals with the transmitted allele, tail DNA was extracted 
and digested with NheI and hybridized with a 3’ probe. As shown in Figure 2.6A, DNA 
from wild-type animals contains a single fragment at 11.1 kb, whereas heterozygous 
animals contain two fragments, an 11.1 kb wild-type fragment and a 9.2 kb knock-in  
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Figure 2.5. Targeting of cDNA encoding HA-∆221EKLF into the endogenous EKLF 
locus. (A) Targeting strategy showing the wild-type EKLF locus, the targeting vector 
used for gene targeting in ES cells, and the targeted locus in which HA-∆221EKLF was 
inserted utilizing the endogenous ATG start site thereby placing the knock-in mutant 
gene under the control of the cis-regulatory elements. Shaded rectangles indicate the 
location of the external probes used for Southern blotting. N = NheI, RV = EcoRV, tk = 
thymidine kinase; dt = diphtheria toxin (B) Southern blot analysis of ES clones using 
EcoRV digest with 5’ probe and NheI digest and 3’ probe.  The wild-type allele is 
detected as an 8.7 kb and an 11.1 kb band, respectively.  The knock-in allele is detected 
as a 6.8 kb and 9.1 kb band, respectively. 
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Figure 2.6. Identification of heterozygous mice expressing HA-∆221EKLF.  (A)  Top 
panel: A schematic diagram of the wild-type allele and knock-in allele with and without 
Neo cassette with the predicted fragment s shown.  Bottom panel: Southern blot analysis 
of mouse tail DNA digested with NheI and hybridized with 3’ probe.  The wild-type band 
is 11.1 kb; knock-in bands 9.2 kb (with Neo) and 8.1 kb (without Neo).  (B)  Top panel: 
A diagram of the wild-type and knock-in alleles.  Colored arrows indicate the location of 
primers used in multiplex PCR.  Dark blue = common forward primer; red = wild-type 
reverse primer; purple = knock-in reverse primer.  Bottom panel: A representative 
photograph of agarose gel electrophoresis.  PCR products amplified with DNA from 
wild-type animals and heterozygous knock-in animals.  The wild-type product is 96 bp 
and the knock-in product is 500 bp. 
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fragment.  Mice in which the Neo cassette has been excised have an 8.1 kb fragment, due  
to loss of a NheI site.  Subsequently, a multiplex PCR method utilizing a common 
forward primer with two different reverse primers was developed to facilitate genotyping 
of the knock-in animals (Figure 2.6B).   PCR of DNA from a wild-type animal amplified 
only a 96 bp fragment with the primers, whereas DNA from a heterozygous animal 
amplified a wild-type fragment of 96 bp and a knock-in fragment of 500 bp with the same 
primers.   
 
Animals heterozygous for the EKLF gene have no discernable phenotype (Nuez 
et al., 1995; Perkins et al., 1995).  There are, however, exceptions where deletion of a 
single gene copy leads to an abnormal phenotype (Johnson et al., 1988; Muroya et al., 
2001; Deutschbauer et al., 2005) whereby the heterozygous mutation on one allele blocks 
the activity of the wild-type protein is still encoded by the normal allele.  To determine 
whether the knock-in mutant protein encoding the Δ221EKLF domain resulted in an 
unexpected phenotype, I evaluated Δ221EKLF heterozygous adult mice.  First, analysis 
of the Mendelian ratio from heterozygous matings demonstrated that Δ221EKLF 
heterozygous animals survive to adulthood without any visible defects (Table 2.2).  As 
expected, these studies also revealed that Δ221EKLF homozygous animals are not viable 
(see Chapter 3).  
 
To evaluate the effects of the heterozygous knock-in allele on mouse 
hematopoiesis, I examined the peripheral blood obtained from Δ221EKLF heterozygous, 
EKLF-null heterozygous, and wild-type mice. Complete blood count (CBC) analysis 
revealed no abnormalities in the hematological parameters measured, including white 
blood cell (WBC) number, red blood cell (RBC) number, hemoglobin (Hgb), hematocrit 
(Hct), and platelet (Plt) count (Table 2.3).  Similarly, Wright-Giemsa staining of the 
peripheral blood smear demonstrated that the circulating erythrocytes in Δ221EKLF mice 
are morphologically similar to those found in wild-type and EKLF-null heterozygous 
animals (Figure 2.7).   
 
 
DISCUSSION 
 
To generate the knock-in alleles of EKLF, I have utilized a lambda phage-based 
recombination method called recombineering.  This method relies on homologous 
recombination in E. coli instead of the traditional subcloning method utilizing restriction 
enzymes and DNA ligases for vector construction, thus eliminating the time and  
difficulty encountered in traditional subcloning methods (Yu et al., 2000; Copeland et al., 
2001; Liu et al., 2003).  The basic steps of recombineering are outlined in Figure 2.1.  
The targeting vectors have been designed in such a way that the cDNA encoding the 
truncation mutation of EKLF (i.e. Δ221EKLF) would be expressed under the endogenous 
EKLF promoter and cis-regulatory elements.  Hence, it is anticipated that the expression 
of the mutant genes, ∆164EKLF, ∆221EKLF, and ∆253EKLF, would resemble that of 
the wild-type endogenous EKLF protein. This approach ensures the proper expression of 
the mutant factor during development and eliminates some of the obstacles in using cell 
lines and artificial rescue constructs (Tsai et al., 1998).  This approach has been used to  
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Genotype     Number of adult animalsa 
 
 
WT/WT                   213 / 154 
 
Δ221EKLF/WT            402 / 307 
 
Δ221EKLF/ Δ221EKLF                              0 / 154  
 
Totalb                       615 
 
a numbers are expressed as observed / expected 
b total number of animals analyzed
Table 2.2. Genotyping of adult animals from heterozygous matings. 
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Table 2.3. Complete blood count analysis of Δ221EKLF heterozygous adult mice. 
 
      Parameter  WT/WT               WT/Δ221EKLF   (p-value)          WT/EKLFnull  (p-value) 
 
      WBC (x103/μL)  6.22 ± 1.73   10.67 ± 2.48 (0.54)   11.40 ± 1.94 (0.13) 
      RBC (x106/μL)  9.09 ± 0.68   8.48 ± 0.51 (0.49)   9.10 ± 0.34 (0.74) 
      Hgb (g/dL)  13.40 ± 0.70   12.83 ± 0.23 (0.28)   13.43 ± 0.42 (0.97) 
      Hct (%)   39.60 ± 1.73   38.30 ± 2.44 (0.25)   39.07 ± 1.88 (0.95) 
      Plt (x103/μL)  824 ± 148   1005 ± 73.5 (0.13)   1048 ± 83 (0.13) 
 
Note: Animals were age and sex matched with 3 adult mice analyzed per cohort.  Data shown are mean ± standard deviation. 
Data were analyzed by the student’s t-test; p-values are listed in parentheses compared to WT. 
 
 
Figure 2.7. Normal circulating erythrocytes in Δ221EKLF heterozygous adult 
animals.  Peripheral blood smear (Wright-Giemsa) of adult animals obtained by retro-
orbital bleeds. Erythrocytes from Δ221EKLF heterozygous animals are morphologically 
similar to erythrocytes from wild-type and EKLF heterozygous animals. Magnification 
x100. 
WT Δ221EKLF / WT WT / -
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demonstrate that myogenin can replace Myf5 in rib cage development (Hanks et al.,  
1998) and that En-2 can replace the function of En-1 in mid-hindbrain development 
(Wang et al., 1996).  Similarly, knock-in mutation of GATA-3 into the GATA-1 locus 
can partially replace the highly homologous factor in erythroid cell development (Tsai et 
al., 1998).   
 
Utilizing the recombineering method, I found it difficult to co-electroporate the 
gap-repaired plasmid and the mini-targeting cassette as originally described (Liu et al., 
2001).  Instead of co-electroporation, I electroporated the mini-targeting cassette into 
electrocompetent EL350 cells which harbored the correct retrieval vector as determined 
by restriction enzyme and sequence analysis. This alternative method required an 
intermediate step to make the retrieval vector-containing EL350 cells electrocompetent 
before electroporation with the mini -targeting cassette.  In contrast, the previously 
described co-electroporation method required a single step in which the retrieval vector 
and mini-targeting cassette DNA were co-electroporated into previously frozen 
electrocompetent EL350 bacterial cells.  The time required for my altered approach was 
not significant and did not greatly affect the total time required to obtain the final 
targeting vectors.  
 
Although the major step of vector construction relied on homologous 
recombination in bacteria by taking advantage of the lambda phage recombination genes, 
certain intermediate steps such as construction of a plasmid to retrieve an 11 kb of 
sequence spanning the EKLF gene from the EKLF BAC and the mini-targeting vectors 
utilized traditional subcloning methods.  As a result, I encountered obstacles common to 
traditional subcloning.  First, I found it difficult to perform a triple ligation (fragments 
AB, XY, and vector) to construct the retrieval vector.  Very few colonies grew on the 
selection plates, and the selected colonies did not harbor the correct plasmid.  To 
circumvent this problem, I increased the ratio of vector to insert in the ligation reaction 
from 1:3 to 1:5 which yielded more colonies to screen.  Similarly, I first tried to construct 
the mini-targeting vector in a single reaction by ligating fragments CD, HA-∆221EKLF, 
Neo-cassette, and EF into a pBlueScript vector.  This yielded no growth on the agar 
plates.  An alternative method was to sequentially subclone each fragment into a vector 
until a complete mini-targeting vector was constructed.  To attempt this altered strategy, I 
had to design new PCR primers for fragments CD and EF with different restriction sites 
to facilitate subcloning.  To my advantage, I used the PL450 vector which already 
contained the Neo cassette to subclone in fragment EF.  Next, I performed a triple 
ligation using increased ratio of vector to inserts to subclone fragments CD and HA-
Δ221EKLF into PL450-EF.   Overall, construction of the mini-targeting vectors utilizing 
traditional subcloning methods proved to be the most time consuming portion of 
generating the knock in alleles of EKLF.  However, I was not hindered by the restriction 
sites as the site for the restriction enzyme of interest was conveniently included in the 
PCR amplification primers. 
 
In my targeting strategy, I have included a Neo cassette adjacent and downstream 
of the Δ221EKLF cDNA to facilitate selection during recombineering in bacteria and 
targeting in ES cells.  Previous studies of knock-out mice have demonstrated the 
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unpredictable phenotypes that can be caused by the retention of Neo cassettes (Olson et 
al., 1996; Pham et al., 1996).   For example, studies in which several specific mutations 
were generated within the human or murine β-globin LCR by insertion of PGK-Neo led 
to abrogation of the expression of multiple globin genes downstream from the cassette.  
However, deletion of the selectable marker cassette resulted in restoration of LCR 
activity, suggesting that the cassette interfered with normal interactions between the LCR 
and downstream regulatory elements in the gene promoters (Pham et al., 1996).  To 
improve Δ221EKLF expression that could be altered by an adjacent downstream Neo 
transgene and to rule out any toxic effects of Neo expression at this locus, the Neo 
cassette in Δ221EKLF heterozygous mice was removed by breeding to a cre transgenic 
mouse line (Lasko et al., 1996).  Subsequent studies in this dissertation have been 
completed in mice in which the Neo cassette has been removed. 
 
Analysis of the Δ221EKLF heterozygous animals provides an early glimpse into 
the functionality of the mutant knock-in protein in vivo.  Given that adult Δ221EKLF 
heterozygous animals develop normally with no discernible phenotype, I speculate that 
the mutant knock-in allele does not exhibit a dominant negative or haploinsufficient 
phenotype.  This observation is supported by my results from the CBC analysis and 
peripheral blood smear which are consistent with a normal hematological phenotype. 
Although the results are not significant (p-value > 0.05), it should be noted that these 
studies were performed with three animals in each cohort.  To minimize the possibility of 
prematurely rejecting a dominant negative phenotype in Δ221EKLF animals, studies in 
Δ221EKLF heterozygous animals should be repeated with a larger sample size.  Indeed, 
it is not uncommon for this phenotype to occur with loss-of-function studies such as been 
described for the transcription factors TWIST (Johnson et al., 1988), GATA3 (Muroya et 
al., 2001), and STAT6 (Bürgis & Gessner, 2007).  For instance, mutant TWIST protein is 
expressed and acts as a dominant negative protein by binding to target promoters and 
then blocking gene transcription (Johnson et al., 1998).  I will demonstrate in Chapter 3 
that the mutant Δ221EKLF protein is expressed in fetal liver and possesses chromatin 
remodeling function in vivo. 
 
  In summary, I have constructed knock-in targeting vectors in which cDNAs 
encoding three different amino terminal truncation mutants of EKLF have been 
engineered into the initiation site of the endogenous murine EKLF gene utilizing the 
recombineering method.  Using this method, I have constructed all three targeting vectors 
in a relatively short time.  Subsequently, the vectors have been used to target the 
endogenous EKLF locus in ES cells via homologous recombination in order to generate 
Δ221EKLF heterozygous animals.  Following the recommendations of my research 
committee, I have chosen to focus my dissertation studies on one strain of mice, the 
∆221EKLF expressing animals.  This domain of EKLF appears to be the most interesting 
to study in vivo as it has been previously identified in cellular assays to possess chromatin 
remodeling properties, however, lacks the ability to transactivate β-globin gene 
transcription (Brown et al., 2002). This animal model will be useful to test my hypothesis 
that expression of Δ221EKLF domain is sufficient to reorganize the local chromatin 
architecture at the β-globin promoter but is insufficient to transcriptionally activate β-
globin in vivo.  In the following chapter, I will describe the functional consequences of 
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expression of Δ221EKLF mutant protein in mice homozygous for the knock-in locus. 
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CHAPTER 3: CHARACTERIZATION OF THE MOLECULAR 
CONSEQUENCES OF Δ221EKLF EXPRESSION IN VIVO 
 
 
INTRODUCTION 
 
 The β-globin locus serves as a paradigm for studying the regulation of a 
multigene locus.  The murine β-globin locus, located on chromosome 7, encodes four 
genes (5’-εy-βh1-βmaj-βmin-3’) which are arranged in the order of their expression during 
ontogeny.  Appropriate regulation of the globin genes in a tissue- and developmental-
specific manner resides in DNA elements located proximal and distal to the genes.  The 
β-globin locus control region (LCR) is a powerful DNA element located far upstream of 
the globin genes.  The LCR is required for high level expression of all the genes during 
development (Grosveld et al., 1987; Bender et al., 2000).  The precise mechanism of how 
the LCR enhances globin gene transcription is still unsettled; however, it is thought to 
involve some method of physical communication between the LCR and the globin genes 
(Bulger & Groudine, 1999; Engel & Tanimoto, 2000).   
 
The murine LCR consists of a series of DNase I hypersensitive sites (HS1-6) that 
contain binding sites for transcriptional factors.  A current hypothesis regards the LCR as 
a holocomplex that enhances globin gene expression through recruitment of chromatin 
remodeling, coactivator, and transcriptional complexes (Wijgerde et al., 1995; Bungert et 
al., 1999; Tolhuis et al., 2002).  Indeed, it has been shown that RNA polymerase II 
(PolII) is recruited to the LCR (Johnson et al., 2003).  Similarly, GATA-1, NF-E2, and 
EKLF have been shown to bind the HS of the LCR (Pevny et al., 1995; Fujiwara et al., 
1996; Forsberg et al., 2000; Zhou et al., 2006).  Furthermore, both GATA-1 and EKLF 
are required for β-globin LCR/promoter interaction (Drissen et al., 2004; Vakoc et al., 
2005). 
 
 The β-globin promoter contains several cis-acting elements that modulate the 
expression of the β-globin gene.  Of these, the CACC motif is of the most interest to the 
present study.  Mutations of this consensus sequence lead to a thalassemic state (Orkin et 
al., 1984) and specifically disrupt the binding of EKLF (Miller & Bieker, 1993; Feng et 
al., 1994).  Disruption of the EKLF gene by homologous recombination has 
demonstrated its non-redundant role during erythroid development.  EKLF-null embryos 
die of a lethal anemia by embryonic day 14-15 of gestation (E14-15), as definitive 
erythroid cells failed to produce β-globin transcripts in vivo (Nuez et al., 1995; Perkins et 
al., 1995).  Further analysis of these EKLF null embryos revealed loss of a 
developmentally specific DNase I hypersensitivity site in the proximal β-globin promoter 
of E14 fetal liver erythroblasts derived from EKLF null embryos (Wijgerde et al., 1996). 
Because the degree of DNase I hypersensitivity of a given locus correlates with 
nucleosomal remodeling (Steger & Workmann, 1996; Pazin et al., 1997), these findings 
are consistent with the idea that EKLF is required for chromatin reorganization at the β-
globin promoter in definitive erythroid cells.  
  
Studies to elucidate the molecular mechanisms by which EKLF modulates 
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chromatin remodeling at the β-globin promoter have relied heavily on in vitro chromatin 
reconstitution assays (Armstrong et al., 1998; Kadam et al., 2000).  These studies have 
identified a SWI/SNF-containing multiprotein complex, E-RC1, which interacts with the 
zinc finger DNA binding domain of EKLF.  This interaction results in chromatin 
remodeling and transcriptional activation of a chromatinized β-globin template.  
Additional evidence supporting this interaction comes from studies demonstrating that 
EKLF interacts with BRG1, a subunit of E-RC1 (Zhang et al., 2001).   Contrary to in 
vitro chromatin assays (Kadam et al., 2000), our laboratory has shown that the zinc finger 
domain alone is not sufficient to remodel chromatin at the β-globin promoter in erythroid 
cell lines (Brown et al., 2002).  Additional sequences in the amino terminus are required 
for EKLF-dependent chromatin remodeling and EKLF interaction with BRG1.  However, 
evidence for a direct interaction between EKLF and SWI/SNF components in vivo is still 
lacking.   
 
To test my hypothesis that expression of Δ221EKLF alone is sufficient to alter the 
local chromatin structure at the β-globin locus in vivo, I will explore the consequences of 
expression of Δ221EKLF and analyze the determinants required for chromatin 
remodeling and β-globin transcription in vivo.  Despite the advances in our understanding 
of the function of EKLF as a chromatin modifier and transcriptional activator, knowledge 
about the direct interaction of EKLF and SWI/SNF components and how EKLF 
modulates chromatin in vivo remains elusive.  Utilizing the newly generated Δ221EKLF 
animals, I show that expression of Δ221EKLF results in embryonic lethality similar to 
mice lacking EKLF.  In stark contrast to lack of EKLF, expression of Δ221EKLF 
completely restores the local chromatin structure at the β-globin promoter.  However, this 
domain is unable to rescue β-globin gene transcription in vivo and fails to recruit GATA-
1 and NF-E2 to the β-globin promoter.  My results suggest that the Δ221EKLF domain is 
sufficient for chromatin reorganization at the β-globin promoter, thus priming the β-
globin gene for transcriptional activation.  Furthermore, I show that nucleosomal 
remodeling and histone modifications at the β-globin promoter are insufficient to activate 
high-level β-globin transcription in vivo. 
 
 
MATERIALS AND METHODS 
 
 
RNA analysis 
 
 Total RNA isolated from fetal liver of E14.5 embryos was subjected to RT-PCR 
analysis.  RNA was extracted using the Trizol method and cDNA was prepared using the 
Superscript III First Strand System (Invitrogen) following the manufacturer’s protocols.  
Briefly, fetal livers from E14.5 embryos were homogenized in Trizol (200-500 µL) 
reagent (Invitrogen).  RNA (10 μg) was treated with Turbo DNase (2 μL)(Ambion) in a 
50 µL reaction to remove genomic DNA contamination.  Following DNase treatment, 
DNase-treated RNA (11 µL) was used for first strand DNA synthesis.  
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For RT-PCR of EKLF gene expression, cDNA (2 μL) was analyzed on a BIO-
RAD PCR machine with the following settings: 94oC for 3 min, then 30 cycles of 94oC 
for 30 sec, 60oC for 30 sec, 72oC for 1 min, followed by 72oC for 10 min.  PCR products 
were analyzed on agarose gels. RT-PCR primers were generated using the Primer 3 
program and are as follows: Exon 1: forward: 5’- 
ATGAGGCAGAAGAGAGAGAGGAG-3’; reverse: 5’-
TGAGTGTACTGATGGAGGGTAAGA -3’; Exon 2: forward: 5’- 
CACAGTACCAAGGCCACTTC -3’; reverse: 5’-GTCCCAGGTCCAAGACAATTC-5’; 
Exons 2/3: forward: 5’-GGGAAGAGCTACACCAAGAGC-3’; reverse: 5’-
GAAGGGACGATGTCCAGTGT-3’; HA-Δ221EKLF: forward: 5’-
TATGCTAGCCTCCCGGGTTA-3’; reverse: 5’-GGTCTCGGCTATCACACCTG-3’; 
HPRT: forward: 5’- GCAGTACAGCCCCAAAATGG-3’; reverse: 5’- 
AACAAAGTCTGGCCTGTATCCAA-3’ (Hodge et al., 2006). 
  
β-globin mRNA and primary transcripts were measured by real time RT-PCR 
utilizing SYBR green fluorescence on an Applied Biosystems Prism 7000 machine. The 
amount of product was determined relative to a standard curve generated from a titration 
of the cDNA. Dissociation curves after amplification showed that primer pairs generated 
single products.  The primers used for real time RT-PCR are shown in Appendix Table 
A.5.  Each sample was run in duplicate with at least five independent experiments 
performed.  
 
 
Protein analysis 
 
Whole cell extracts were prepared from fetal liver of E14.5 embryos using the P-
TER reagent (Pierce) according to the manufacturer’s recommendations.  Protein 
concentration was measured by the Bradford Assay reagent (BioRad).  One hundred 
micrograms of protein was mixed with loading dye and denatured by boiling for 5 min.  
The proteins were resolved on a 15% SDS-PAGE gel followed by wet transfer.  The blots 
were blocked in 5% milk in 0.1% PBS/Tween-20 for 1 h at room temperature with 
constant rocking.  Primary antibody at 1:200 dilution or 1:400 dilution for HA and EKLF, 
respectively, was added and the blots were probed overnight in the cold room with 
constant rocking.  Blots were washed once for 15 min and twice for 5 min times with 
0.1% PBS/Tween-20.  Secondary antibody conjugated with horseradish peroxidase 
(HRP) was added at a dilution of 1:1000 and incubated for 1 h at room temperature.  The 
blots were washed three times as before with 0.1% PBS/Tween-20.  Peroxidase activity 
was visualized by enhanced chemiluminescence (ECL) using Western blotting detection 
reagents from Amersham Biosciences.  The Western blots were probed with HA-
antibody (Santa Cruz), Cunningham laboratory generated EKLF-antibody directed 
toward the zinc fingers (J.M.C unpublished), and actin-HRP (Abcam) as loading control. 
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Cytospin, sections, and staining 
 
Fetal liver erythroblasts from E14.5 embryos were made into single cell 
suspension in D10 (DMEM + 10% FBS) and cytocentrifuged onto glass slides. For 
immuno-localization studies, the cells were fixed in 4% formaldehyde for 20 min, 
permeabilized with 0.1% Triton X-100-PBS, and blocked in 10% normal donkey serum 
(Jackson ImmunoResearch) for 1 hr at room temperature. Anti-HA antibody was added 
to the slides and incubated at 4°C overnight. A secondary antibody, conjugated to FITC 
(Molecular Probes), was applied for another 2 h of incubation at room temperature. DNA 
staining was carried out using DAPI (4', 6’diamidino-2-phenylindole) (Vector Shield).  
Slides were visualized with a Leica DM IRB fluorescence microscope.   
 
Staining with benzidine-Giemsa (Sigma) was performed according to the 
manufacturer’s recommendations.  Briefly, cytospin preparations were fixed in cold 
methanol for 2 min, allowed to air dry, and then stained in benzidine for 20 min.  After 
20 min, the slides were rinsed with distilled water and placed in Giemsa stain for another 
20min.  Slides were rinsed with water, air dried, and mounted with cover slips.   
 
To prepare sections of the fetal liver, wild-type, Δ221EKLF, and EKLF-null 
E14.5 fetal livers were immersion fixed in 4% formalin overnight, or longer, before 
submission to the Core Pathology Department at the University of Chicago.  The fetal 
livers were processed for sectioning and stained with H&E and Prussian blue.  Slides 
were viewed under a Nikon Eclipse E400 microscope fitted with a camera. 
 
 
DNase I sensitivity assays 
 
DNase I sensitivity assays were performed essentially as described by McArthur 
et al. (2001) with slight modifications.  Briefly, fetal livers were harvested from E14.5 
mouse embryos and made into single cell suspension by passing through a 70 µm cell 
strainer.  Cells (6 x 106) were washed once with cold PBS and resuspended with 5 ml of 
buffer A (15 mM Tris HCl (pH 7.6), 60 mM KCl, 15 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.5 mM spermidine, 0.15 mM sperminine). Cells were lysed in the presence of 
0.5 % (v/v) NP40, and nuclei were collected and resuspended in 1.2 mL of digestion 
buffer (buffer A supplemented with 3 mM CaCl2, 75 mM NaCl).  200 µL of the nuclei 
mixture was added to Eppendorf tubes containing 50 µL of the digestion mixture 
containing 0-18 units of DNase I (ROCHE).  Digestions were carried out at 37 °C for five 
minutes before being stopped by the addition of an equal volume of stop buffer (0.1 M 
NaCl, 0.1 % (w/v) SDS, 50 mM Tris-HCl (pH 8.0), 100 mM EDTA). The samples were 
treated with proteinase K (500 µg/mL) at 55oC overnight and DNA recovered by 
extraction with phenol/chloroform and precipitation in ethanol. The DNA was then 
dialyzed against two changes of TE buffer, re-precipitated and diluted in water to a 
concentration of 10 ng/µL as measured by spectrophotometry.  
 
Real time PCR was performed on the DNA samples using SYBR green mix in a 
total reaction volume of 25 µL.  To quantify the amount of DNA remaining following 
 41
DNase I treatment, a standard curve was generated from titration of undigested genomic 
DNA.  The values at each concentration of DNase I was normalized to a previously 
determined DNase I insensitive gene, Nf-M (McArthur et al., 2001).  Dissociation curves 
after amplification showed that a single product was formed for each primer pair.  The 
primer pairs used were: βmaj promoter forward: 5’-
CAGGGAGAAATATGCTTGTCATCA-3’ and βmaj promoter reverse:  
5’-GTGAGCAGATTGGCCCTTACC-3’; Nf-M forward: 5′-
GCTGGGTGATGCTTACGACC-3′ and Nf-M reverse: 5′-
GCGGCATTTGAACCCTCTT-3′ (McArthur et al., 2001). 
 
 
Chromatin immunoprecipitation assays 
 
ChIP assays were performed as previously described (Forsberg et al., 2000; 
Kiekhaefer et al., 2002), with slight modifications.  Fetal livers from E13.5  mouse 
embryos were harvested and passed separately through a 70 µm cell strainer into 20 ml of 
DMEM-based medium supplemented with 10% FBS.  Protein-DNA cross-linking was 
performed by incubating suspensions of fetal liver (at a concentration of 106 cells/mL) 
with formaldehyde at a final concentration of 0.8% for 10 min at room temperature with 
gentle agitation. Glycine (0.125 M) was added to quench the reaction. Cells were then 
collected by centrifugation at 1000 rpm for 5 min, washed in cold PBS and a second wash 
in cold PBS supplemented with Roche complete EDTA-free protease inhibitor and PMSF 
(Fluka).  Cross-linked cells were snap frozen and stored at -70oC until further processing.  
 
Immunoprecipitation was performed with 1 x 107 cells per IP condition.  The 
buffer composition used in the ChIP assay is listed in the Appendix Table A.3. Nuclei 
were isolated by incubation in cell lysis buffer for 10 min on ice followed by 
centrifugation at 600 × g for 5 min. Nuclei were lysed in nuclei lysis buffer for 10 min on 
ice. The lysate was sonicated for 20 minutes total using the Bioruptor sonicator 
(Diagenode, Belgium) set on High power and cycles of 30 seconds ON and 30 seconds 
OFF to obtain an average size of 500 bp. Soluble chromatin was diluted 1:4 with IP 
dilution buffer and precleared by addition of 5 µL/mL preimmune serum followed by 50 
µL of salmon sperm DNA/Protein A agarose (Millipore). An aliquot (1/10th of the total 
volume) of precleared chromatin was removed (input) and used in the subsequent PCR 
analysis. The remainder of the chromatin was incubated with and without primary 
antibodies for 4 hours at 4oC. Immune complexes were collected by incubation with 75 
µL salmon sperm DNA/Protein A agarose (Millipore) for 2 h at 4°C. A control sample 
was prepared in all experiments in which IP wash buffer 1 was added instead of 
chromatin.  Protein A agarose pellets were washed twice with 500 µL aliquots of IP wash 
buffer 1, once with IP wash buffer 2, and twice with TE buffer.  Immune complexes were 
eluted twice with 100 µL of IP elution buffer made fresh and NaCl (0.4 M) were added, 
and cross-links were reversed by incubation overnight at 65°C. Samples were digested 
with Proteinase K (0.3 mg/mL) for 2 h at 45°C. DNA was purified by Qiaquick PCR 
purification kit (QIAGEN) and eluted twice with 50 µL elution buffer each time.  
 
Immunoprecipitated DNA (2 µL) was analyzed by real-time PCR (Applied 
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Biosystems Prism 7000) with the appropriate primer pairs.  Samples from at least three 
independent immunoprecipitations were analyzed. Product was quantified by SYBR 
green fluorescence in 25 µL reactions, and the amount of product was determined relative 
to a standard curve generated from a titration of input chromatin.  Dissociation curves 
after amplification showed that primer pairs generated single products.   
 
Primer pairs used in ChIP analysis are listed in Appendix Table A.4.  The 
antibodies used in ChIP analysis were anti-HA antibody (Santa Cruz, sc-805x), anti-
acetylated histone H3 antibody (Upstate, 06-599), anti-RNA PolII (Santa Cruz, sc-899x), 
anti-GATA-1 (Abcam, ab11963 ), and anti-NF-E2 (Santa Cruz, sc-291x ).  Normal rabbit 
IgG (Santa Cruz, sc-2027) was used as a control. 
 
 
RESULTS 
 
 
Δ221EKLF homozygous animals die in utero and exhibit ineffective erythropoiesis 
 
Initial studies analyzing the matings of Δ221EKLF heterozygous animals 
(described in Chapter 2) revealed that Δ221EKLF homozygous adult mice are not viable.  
Of 615 adult mice genotyped, no live born Δ221EKLF homozygous animals were 
observed.  This observation is consistent with an embryonic lethal phenotype.   
 
To determine when the animals succumb in utero, timed pregnancies were 
established.  These studies revealed that Δ221EKLF homozygous animals died by day 
15.5 (E15.5) of gestation, a similar timepoint to EKLF-null embryos (Nuez et al., 1995; 
Perkins et al., 1995) (Table 3.1).  Furthermore, gross examination of the Δ221EKLF 
embryos at day 15.5 of gestation revealed a pale embryo with a smaller and paler fetal 
liver as compared to a wild-type littermate control (Figure 3.1).  These observations are 
consistent with the phenotype previously described in EKLF-null embryos of similar 
chronology (Perkins et al., 1995).   
 
The Δ221EKLF embryos appeared to lack any blood in the circulatory system, 
consistent with defective erythropoiesis in vivo.  This observation was supported by 
benzidine-Giemsa staining of cytospun preparations of fetal liver erythroblasts and 
Prussian blue staining of fetal liver sections.  As shown in Figure 3.2, there are very few 
benzidine-positive cells in fetal liver from Δ221EKLF embryo.  To quantify the 
difference, the number of benzidine-positive cells was manually counted under low 
magnification.  As shown in Table 3.2, similar to EKLF-null embryos, Δ221EKLF 
embryos had 33% fewer benzidine-positive cells when compared to wild-type embryos.    
Benzidine stains for hemoglobin (i.e. brown color), a hallmark of terminal erythroid 
differentiation (Zhang et al., 2003).  These observations, thus, suggest a failure of the 
Δ221EKLF-expressing erythroblasts to properly accumulate hemoglobin and execute 
terminal erythroid differentiation as previously demonstrated in EKLF-null cells (Drissen 
et al., 2005; Pilon et al., 2008).  Furthermore, the Δ221EKLF erythroblasts, like EKLF-
null erythroblasts, are misshapen as evident by the irregularly shaped cell membrane  
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Table 3.1. Genotyping of embryos at different stages of gestation from heterozygous 
matings. 
 
Genotype          E10.5 a         E13.5       E14.5     E15.5          Adult 
 
WT/WT          12/12         30/27       109/89     17/29         213/154   
 
Δ221EKLF/WT         22/23         57/55       175/179     29/27         402/307 
 
Δ221EKLF/Δ221EKLF      13/12         22/27        73/89      4/13         0/154 
 
Totalb                        47          109          357       53    615 
 
a numbers are expressed as observed/expected 
b total number of animals analyzed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
C D
E F
WT
WT
Δ221
Δ221
KOWT         Δ221
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Figure 3.1.  Δ221EKLF embryos are anemic. (A-D) Photographs of wild-type and 
Δ221EKLF embryos at E15.5.  The homozygous Δ221EKLF embryo is pale and slightly 
smaller compared to wild-type littermate. A marked deficit of circulating red cells is 
evident. (E) Fetal liver from E15.5 wild-type and Δ221EKLF embryos.  The Δ221EKLF 
fetal liver is smaller and paler than fetal liver from a littermate control. (F) Photograph of 
E15.5 EKLF-null embryo.  The EKLF-null embryo is pale. 
 
WT Δ221 KO
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Table 3.2. Quantitative analysis of benzidine-positive E14.5 fetal liver erythroblasts. 
 
 
Genotype    # benzidine-positive cells/0.24mm2 field 
 
 
WT            25 ± 4.2 
 
Δ221EKLF / Δ221EKLF           8 ± 2.7  
 
KO                 7 ± 1.3 
 
Note: Data shown as average number of benzidine-positive cells counted from three 
different fields (± SD).  Fetal liver from 2-3 embryos of each genotype were analyzed. 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Defects in cell shape and content in Δ221EKLF fetal liver erythroblasts.  
Cytospin preparations of E14.5 fetal liver erythroid cells were stained with benzidine-
Giemsa.  There are fewer benzidine-positive cells (denoted by arrowheads) from 
Δ221EKLF fetal liver. Defective erythroid cell membrane is noted in Δ221EKLF.  
Original magnification x 100.  
 
 
compared to wild-type erythroblasts.  This observation is consistent with the idea that 
Δ221EKLF erythroblasts have membrane defects as has been described in EKLF-null 
cells (Drissen et al, 2005; Hodge et al., 2006).  Similarly, Prussian blue staining of fetal 
liver sections revealed excess iron deposits (i.e. blue particles) in the fetal liver of  
Δ221EKLF embryos (Figure 3.3, bottom panel).  This observation is consistent with the 
idea that Δ221EKLF expressing erythroblasts fail to properly accumulate hemoglobin 
during terminal erythroid differentiation similar to that described in erythroblasts lacking 
EKLF (Perkins et al., 1995; Drissen et al., 2005).  Together, these observations support 
the idea that Δ221EKLF mice exhibit a phenotype consistent with ineffective 
erythropoiesis, comparable to EKLF-null mice (Nuez et al., 1995; Perkins et al., 1995). 
 
 
∆221EKLF is expressed in fetal liver  
 
To evaluate the expression of the mutant knock-in allele in vivo, RNA from fetal 
liver erythroblasts derived from E14.5 embryos was analyzed by RT-PCR.  As shown in 
Figure 3.4A, the mutant transcript is detected only in RNA extracted from Δ221EKLF 
fetal liver erythroblasts.  Furthermore, the downstream endogenous exons 2 and 3 of 
EKLF, which were left intact in the targeting strategy, are not transcribed in these mice.  
This observation is expected given that a polyadenylation signal was included in the 
targeting strategy to prevent interference from the endogenous downstream exons.  Thus, 
it appears that the mutant knock-in allele is indeed transcribed in vivo. 
 
Because mRNA expression does not necessarily correlate with protein abundance 
(Greenbaum et al., 2003), Western blotting analysis was performed to detect the 
Δ221EKLF mutant protein in vivo.  The ∆221EKLF encoding cDNA included a HA 
epitope tag at the amino terminus to facilitate immunological detection.  Using HA-
specific anti-sera, the mutant protein was detected in the fetal liver (Figure 3.4B).  
However, the results do not compare the level of mutant protein expression to that of 
wild-type EKLF protein.  Anti-EKLF antibodies are commercially available, however, 
the epitopes are directed to sequences outside of the ∆221EKLF domain.  Previously, our 
laboratory had generated an antibody directed against the zinc finger DNA-binding 
domain of EKLF (J.M.C. unpublished).  Using this antibody, the mutant Δ221EKLF 
protein was detected in the fetal liver of Δ221EKLF heterozygous and homozygous 
embryos (Figure 3.4C) albeit at a lower level than wild-type EKLF protein.  The lower 
level of knock-in protein could result from instability or altered regulation of the knock-
in protein.  However, I have shown that Δ221EKLF protein retains full chromatin 
remodeling properties in a similar manner to wild-type EKLF protein (see below).  More 
importantly, the endogenous wild-type EKLF protein is not detected in the fetal liver of 
homozygous knock-in animals.  The subcellular localization of the mutant protein was 
analyzed by immuno-staining.  As shown in Figure 3.5 (panels j-l), the mutant protein 
stained with anti-HA antibody co-localizes in the nucleus as indicated by DAPI staining.  
Taken together, these results demonstrate that the mutant knock-in protein is expressed in 
the fetal liver and is localized to the nucleus. 
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Figure 3.3. Accumulation of hemosiderin in fetal liver of mice expressing 
Δ221EKLF.  Paraffin-embedded sections of fetal liver from E14.5 embryos: (a-c) 
hematoxylin and eosin stain and (d-f) Prussian blue stain.  Hemosiderin is detected as 
blue deposits in the fetal liver. Original magnification x 400. 
WT KO
WT KOΔ221EKLF
Δ221EKLF
a. b. c.
d. e. f.
Figure 3.4.  Expression of Δ221EKLF in fetal liver.  (A)  Top Panel:  Schematic of the 
wild-type and knock-in alleles of EKLF.  Arrows indicate the primers used in RT-PCR.  
Bottom Panel: Representative picture of agarose gel demonstrating that Δ221EKLF 
transcripts are amplified only with RNA extracted from fetal liver of homozygous 
Δ221EKLF embryos at E14.5.  Additionally, downstream exons 2 and 3 of the 
endogenous EKLF locus are not transcribed in these animals.  HPRT transcripts are 
detected as loading control. (B-C)  Western blot analysis demonstrating that Δ221EKLF 
knock-in protein is expressed in fetal liver.  Whole cell extracts were prepared from fetal 
liver of E14.5 wild-type, Δ221EKLF heterozygous, and Δ221EKLF homozygous 
embryos.  Whole cell extracts from J2e cell lines were included as controls.  (B) An anti-
HA antibody was used to detect the HA-tagged mutant protein (HA-Δ221EKLF).  (C) 
Anti-EKLF antibody generated in our laboratory (J.M.C. unpublished) was used to detect 
wild-type EKLF and mutant Δ221EKLF proteins.  β-actin expression was detected as 
loading controls. 
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Figure 3.5. Localization of Δ221EKLF knock-in protein.  Cytospin preparations of 
fetal liver erythroblasts from E14.5 Δ221EKLF homozygous embryos were stained with 
anti-HA antibody (j-l).  The slides were mounted with VECTASHIELD® mounting 
medium containing DAPI.  Wild-type fetal liver erythroblasts, which lack the HA tag, 
served as a negative controls (g-i) while the inducible JH31 cellular system containing a 
HA-EKLF-ER fusion protein served as positive controls (a-f).  In the absence of the ER 
ligand, HA-EKLF-ER protein is bound to chaperone proteins in the cytoplasm but can be 
translocated inside the nucleus in the presence of Tamoxifen. 
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Expression of Δ212EKLF is sufficient for ß-globin promoter remodeling 
 
 To determine the functional consequences of Δ221EKLF on the chromatin 
structure in vivo, nucleosomal remodeling at the β-globin promoter was determined by a 
real time PCR-based DNase I hypersensitivity assay (McArthur et al., 2001).  Chromatin 
prepared from fetal liver nuclei was incubated with increasing amounts of the DNase I 
enzyme.  DNA was purified and analyzed by real time PCR.  The sensitivity is plotted as 
a percent of DNA remaining at different concentrations of DNase I and normalized to an 
internal control region from the neurofilament Nf-M gene located on murine 
chromosome 14.  Nf-M is relatively resistant to DNase I digestion, although at higher 
concentrations of DNase I and longer incubation time period, the DNA at this region is 
digested eventually by DNase I.  As shown in Figure 3.6, chromatin extracted from 
Δ221EKLF fetal liver erythroblasts is sensitive to treatment with increasing amounts of 
DNase I at a level comparable to chromatin from derived from wild-type erythroblasts.  
In contrast, and consistent with previous observations (Wijgerde et al., 1996), chromatin 
derived from EKLF-null erythroblasts are relatively insensitive to DNase I treatment up 
to 18 U of enzyme.  The amount of sensitivity is erythroid cell-dependent, and the fetal 
liver has previously been determined to be greater than 20% hepatocytes at this stage 
(McArthur et al., 2001). 
 
 
Expression of Δ221EKLF induces histone modifications at the β-globin promoter 
 
To further explore the role of Δ221EKLF in reorganizing the chromatin 
architecture at the β-globin gene promoter, the acetylation and methylation patterns of 
histone H3 (H3) across the β-globin locus was determined by ChIP assays.  Extending 
the results from the DNase I HS assay, I hypothesized that the Δ221EKLF domain is 
sufficient to induce acetylation of histone H3 and methylation at K4.  As shown in Figure 
3.7, histones were acetylated at wild-type levels at the β-globin promoter in Δ221EKLF 
erythroblasts.  Interestingly, the level of acetylation was comparable to EKLF-null 
erythroblasts at the 3’ coding region of the β-globin gene in Δ221EKLF erythroblasts.  
This observation is consistent with the idea of a lack of significant β-globin elongation in 
Δ221EKLF erythroblasts (Sawado et al., 2003).  By contrast, the acetylation pattern at 
the β-globin HS2 was comparable in wild-type, Δ221EKLF, and EKLF-null erythroblasts, 
suggesting acetylation of HS2 of the LCR occurs independently of EKLF.    Similarly, 
analysis of the trimethylation pattern of lysine 4 of histone H3 revealed comparable 
levels of trimethylation at the β-globin HS2; however, trimethylation at the β-globin 
promoter was increased in Δ221EKLF erythroblasts to a comparable level observed in 
wild-type erythroblasts (Figure 3.8).  This modification, trimethylated H3K4, has been 
associated with active genes in vivo (Bernstein et al., 2005).  Taken together, the data 
suggest that expression of the Δ221EKLF domain is sufficient for full and appropriate 
chromatin remodeling activity in vivo. 
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Figure 3.6. DNase I sensitivity at the β-globin promoter in Δ221EKLF fetal liver 
erythroblast. Plot of a quantitative real time PCR based DNase I hypersensitivity assay 
used to analyze the region of murine βmaj promoter in fetal liver from E14.5 wild-type, 
Δ221EKLF, and EKLF-null embryos.  The results are plotted as the percent of DNA 
remaining after 5 min incubation with increasing amounts of DNase I enzyme normalized 
with the relatively insensitive Nf-M gene.  Data shown are averages of at least three 
independent experiments.  Error bars indicate the standard error of the mean.  Asterisks 
denote p-value compared to KO. * = p-value <0.05; ** = p-value <0.001. 
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Figure 3.7. Global acetylation of histone H3 across the β-globin locus.  Top panel: 
schematic of murine β-globin locus with location of primer pairs used in ChIP analysis 
denoted by solid lines.  Bottom panel: pattern of histone H3 acetylation across the β-
globin locus was analyzed by ChIP assay using anti-acetylated histone H3 (AcH3) 
antibody. Data shown are averages of at least five independent experiments performed in 
duplicate (mean ± SEM).  NS = not significant. IVR = intervening region in the β-globin 
locus. 
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Figure 3.8. Trimethylation pattern at lysine 4 of histone H3.  The trimethylation at 
lysine 4 of histone H3 (Me3H3K4) at the β-globin HS2 and promoter sequences was 
analyzed by ChIP assay.  Data shown are averages of at least five independent 
experiments performed in duplicate (mean ± SEM).  NS = not significant. 
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Δ221EKLF binds to erythroid-specific gene loci 
 
The zinc finger DNA binding domain of EKLF recognizes and binds to the 
consensus sequence CCNCNCCCN found at many erythroid gene loci.  To explore 
whether the mutant ∆221EKLF protein was capable of binding to known EKLF 
regulatory sequences in vivo, chromatin immunoprecipitation (ChIP) was performed with 
a HA-specific anti-serum.  In contrast to erythroid cells lacking EKLF, fetal liver 
erythroblasts expressing the ∆221EKLF protein demonstrated appropriate binding of the 
chromatin remodeling encoding domain to known-EKLF regulatory sequences at the β-
globin locus, but not to non-erythroid gene promoters (i.e. RPII215).  As shown in Figure 
3.9, ∆221EKLF protein binds to the β-globin HS2, the β-globin gene promoter as well as 
to the promoters of two erythroid genes, AHSP (Pilon et al., 2006) and α-globin (Shyu et 
al., 2005).  In contrast, the mutant protein did not bind to regions that do not contain 
EKLF binding sites, including an intervening region in the β-globin locus (IVR), 
downstream region of the β-globin gene, and the non-erythroid gene RPII215 (Im et al., 
2005).  The RPII215 gene, located on murine chromosome 11, encodes the largest 
subunit of RNA polymerase II (Pravtcheva et al., 1986).  These results confirm that the 
mutant protein expressed in fetal liver is capable of binding to the EKLF regulatory 
sequences in vivo. 
 
 
Expression of Δ221EKLF is insufficient for high-level β-globin transcription 
 
EKLF is essential for β-globin gene transcription.  Although previous cellular 
studies have demonstrated that a larger domain of EKLF is required and sufficient to 
activate β-globin gene transcription (Brown et al., 2002), it is not clear what determinants 
are required in vivo.  To determine if expression of ∆221EKLF was sufficient for 
activation of gene transcription in vivo, the expression level of the adult β-globin gene in  
∆221EKLF fetal liver erythroblasts from E14.5 embryos were analyzed by real time RT-
PCR.  Similar to complete loss of EKLF, there was minimal gene expression, or 
transcription as assayed by primary transcript analysis, of the β-globin gene in 
∆221EKLF erythroblasts compared to wild-type erythroblasts (Figure 3.10).  These 
results suggest that additional amino terminal sequences are required for EKLF-
dependent gene activation in vivo.  Moreover, the lack of β-transcripts suggests that these 
animals succumbed in utero, at least in part, from a severe anemia in a similar manner to 
EKLF-null animals (Nuez et al., 1995; Perkins et al., 1995). 
 
 
Differential binding of factors at the β-globin LCR and promoter 
 
The failure of Δ221EKLF to activate β-globin transcription, despite nearly normal 
promoter remodeling as determined by DNase I HS formation and hyperacetylation of 
histones at the β-globin promoter, led me to explore the role of Δ221EKLF in factor 
recruitment to the β-globin LCR and promoter. First, occupancy of PolII at the β-globin 
locus was examined by ChIP assay with anti-PolII antibody capable of detecting both 
phosphorylated and unphosphorylated forms of PolII.  Phosphorylation of PolII serine 5  
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A. 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
C. 
 
Figure 3.9. Differential binding of Δ221EKLF to erythroid-specific gene loci.  (A)  
Schematic of murine β-globin locus with location of primer pairs used in ChIP analysis 
denoted by solid lines.  (B)  The binding of Δ221EKLF across the β-globin locus was 
examined using ChIP assays with anti-HA specific anti-serum. (C)  The binding of 
Δ221EKLF at other erythroid-specific gene promoters (positive controls) and a non-
erythroid gene promoter (negative control).  Data shown are averages of at least five 
independent experiments performed in duplicate (mean ± SEM).  NS = not significant. 
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Figure 3.10. Lack of β-globin transcripts in Δ221EKLF fetal liver erythroblasts in 
vivo.  RNA was extracted from fetal liver of E14.5 wild-type, Δ221EKLF, and EKLF-
null embryos and treated with Turbo DNase prior to cDNA synthesis.  β-globin gene 
expression (as determined by mRNA levels) and transcription (as assayed by primary 
transcripts) were analyzed by real time RT-PCR.  Data shown are averages of at least five 
independent experiments (mean ± SEM). 
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 is an essential step in transition from a stalled to an elongating polymerase (Phatnami 
&Greenleaf, 2006).  Not surprisingly, there was increased occupancy of PolII at the β-
globin promoter and 3’ of the gene in wild-type erythroblasts (Figure 3.11), consistent 
with active β-globin transcription.  In contrast, minimal RNA polymerase II occupancy 
was observed at the β-globin promoter in Δ221EKLF expressing cells of a similar 
chronology.  Furthermore, the amount of PolII at the 3’ region of the β-globin gene was 
not significantly increased, consistent with the idea of a paused PolII complex at the β-
globin promoter (Phatnami & Greenleaf, 2006).  This observation is supported by the β-
globin transcript data, demonstrating a significant reduction in β-globin transcripts in 
Δ221EKLF erythroblasts as compared with wild-type erythroblasts (Figure 3.10).  When 
compared to EKLF-null cells, occupancy of PolII at the β-globin promoter was 
approximately 3-fold higher in Δ221EKLF cells (p-value <0.0001).  By contrast, similar 
levels of PolII were recruited to HS2 of the LCR in wild-type, Δ221EKLF, and EKLF-
null cells, consistent with the idea that EKLF does not mediate this step.  Furthermore, 
this result is not surprising given previous studies have demonstrated that recruitment of 
PolII to the LCR occurs independent of recruitment to and activation of the β-globin 
promoter (Johnson et al., 2003).  Importantly, my results support a role for EKLF in 
recruitment of PolII to the β-globin promoter, as has been previously described for 
GATA-1 and NF-E2 (Johnson et al., 2001). 
 
The β-globin promoter contains numerous binding sites for erythroid-specific and 
ubiquitous transcription factors that regulate appropriate high-level expression of the β-
globin gene.  EKLF, GATA-1, and NF-E2 are among the best characterized 
transcriptional activators and have been shown to bind the β-globin promoter sequences 
and DNase HS sites (HS) at the LCR (Mahajan et al., 2007).  To elucidate the role of 
Δ221EKLF in EKLF-mediated transactivation of the β-globin gene, I analyzed the 
recruitment GATA-1 and NF-E2 to the HS2 of the LCR and β-globin promoter in 
Δ221EKLF expressing fetal liver erythroblasts (Figure 3.12).  The occupancy of NF-E2 
and GATA-1 at an intervening region (IVR) on the β-globin locus and the downstream 
region of the β-globin gene were included as negative controls.  Chromatin 
immunoprecipitation analysis revealed a comparable level of NF-E2 occupancy at the β-
globin HS2; however, NF-E2 occupancy at the β-globin promoter was significantly 
reduced in Δ221EKLF erythroblasts as compared with wild-type erythroblasts (Figure 
3.12A).  These results are consistent with previous reports that demonstrate NF-E2  
recruitment to HS2 of the LCR and β-globin promoter is essential for activation of β-
globin transcription (Forsberg et al., 2000; Sawado et al., 2003).  Similarly, GATA-1 
occupancy at the β-globin HS2 was comparable in wild-type, Δ221EKLF, and EKLF-null 
erythroblasts (Figure 3.12B).  In contrast, GATA-1 occupancy at the β-globin promoter 
was significantly reduced in Δ221EKLF as compared to wild-type erythroblasts.  These 
observations are consistent with the role for GATA-1 at HS2 of the LCR in co-activator 
and PolII recruitment to the β-globin promoter (Cho et al., 2008).  Additionally, my 
results in Δ221EKLF-expressing cells suggest that a larger amino terminal domain of 
EKLF is required and necessary for recruitment of GATA-1 and NF-E2 to the β-globin 
promoter.  
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Figure 3.11. Lack of RNA polymerase at the β-globin promoter in Δ221EKLF 
expressing cells.  The amount of total PolII occupancy across the β-globin locus was 
examined by ChIP analysis with the polyclonal anti-PolII antibody.  Data shown are 
averages of at least five independent experiments performed in duplicate (mean ± SEM).  
NS = not significant. 
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A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Binding of erythroid-specific transcription factors at the β-globin 
promoter in vivo.  Binding of (A) NF-E2 and (B) GATA-1 across the β-globin locus was 
analyzed by ChIP assay in fetal liver from E14.5 wild-type, Δ221EKLF, and EKLF-null 
embryos. Data shown are averages of at least three independent experiments performed 
in duplicate (mean ± SEM).  NS = not significant. 
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DISCUSSION 
 
 The studies in this chapter are aimed at exploring the hypothesis that expression 
of Δ221EKLF alone is sufficient for altering the local chromatin structure   
at the β-globin promoter in vivo.  Furthermore, these studies have provided significant 
insights into EKLF-mediated activation of β-globin transcription in vivo.  
 
 
Expression of Δ221EKLF is not sufficient to rescue the EKLF-null phenotype 
 
I have demonstrated in the present study that expression of Δ221EKLF in vivo 
cannot rescue the EKLF null phenotype.  Like mice lacking EKLF (Nuez et al., 1995; 
Perkins et al., 1995), Δ221EKLF mice exhibit a phenotype consistent with ineffective 
erythropoiesis and die by E15.5 of gestation.  The Δ221EKLF embryo is anemic with few 
hemoglobin-containing erythroblasts in the fetal liver, consistent with a block in erythroid 
differentiation.   Expression of Δ221EKLF protein has been confirmed in vivo.  Although 
the mutant Δ221EKLF protein appears to be expressed at lower levels than wild-type 
EKLF protein, this alone cannot account for the observed phenotype of Δ221EKLF mice 
given that the mutant protein retains full and appropriate chromatin remodeling properties 
(see discussion below).  Previous studies in our laboratory have shown that this domain 
of EKLF cannot activate β-globin gene transcription in erythroid cell lines (Brown et al., 
2002).  Thus, it was anticipated that expression of Δ221EKLF in a whole animal model 
would result in embryonic lethality reminiscent of the EKLF-null mice. 
 
 
Expression of Δ221EKLF is sufficient for nucleosomal remodeling and histone 
modifications in vivo 
  
Previous studies analyzing the distinct domains of EKLF in erythroid cell lines 
demonstrated that chromatin remodeling and transcriptional activation functions of EKLF 
are separable (Brown et al., 2002).  Conclusions from these studies are that sequences 
between amino acid 221-253 are necessary and sufficient for chromatin remodeling at the 
β-globin promoter while additional N-terminal amino acid sequences are required for 
transactivation of β-globin gene transcription.  Moreover, expression of Δ221EKLF in an 
erythroid cell line results in DNase I HS formation at the β-globin promoter to wild-type 
levels. 
 
My studies expand on these conclusions and provide novel results on the 
chromatin remodeling property of EKLF in vivo.  Indeed, DNase I hypersensitivity assays 
reveal that chromatin derived from Δ221EKLF fetal liver erythroblasts is as sensitive to 
DNase I treatment as wild-type chromatin, whereas chromatin from EKLF-null 
erythroblasts is relatively insensitive (Figure 3.6).  Because the degree of DNase I 
sensitivity corresponds with nucleosomal remodeling (Steger & Workman, 1996; Pazin et 
al., 1997), the data strongly suggest that expression of Δ221EKLF is sufficient for 
nucleosomal remodeling at the β-globin promoter in vivo.  Previous studies analyzing the 
role of EKLF in chromatin remodeling have relied on in vitro chromatin reconstitution 
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assays.  These studies have identified a SWI/SNF-containing multiprotein complex, E-
RC1, which interacts with the zinc finger DNA binding domain of EKLF (Armstrong et 
al., 1998; Kadam et al., 2000).  This interaction results in chromatin remodeling and 
transcriptional activation of a chromatinized β-globin template.  Additional evidence 
supporting this interaction comes from studies demonstrating that EKLF interacts with 
BRG1, a subunit of E-RC1 (Zhang et al., 2001).  However, evidence for a direct 
interaction between EKLF and SWI/SNF components in vivo is still lacking; however, 
BRG1 is a highly attractive candidate to explore. 
 
Similarly, I show that expression of Δ221EKLF is sufficient to induce histone 
modifications in vivo.  First, global acetylation of histone H3 (AcH3) at the β-globin 
promoter is increased in Δ221EKLF erythroblasts to an equivalent level as observed in 
wild-type erythroblasts (Figure 3.7).  Similarly, trimethylation at lysine 4 of histone H3 at 
the β-globin promoter is increased to wild-type levels in Δ221EKLF erythroblasts (Figure 
3.8).  It is known that higher acetylation particularly of histones H3 and H4 are associated 
with the ‘opening’ of chromatin for transcription (Yan & Boyd, 2006). Furthermore, 
trimethylation at lysine 4 of histone H3 has been associated with promoters of active 
genes (Bernstein et al., 2005).  My results not only extend these observations to include 
EKLF, but also provide evidence that the Δ221EKLF domain alone is sufficient for high-
level H3 acetylation at the β-globin promoter. EKLF has previously been shown to 
interact with the histone acetyltransferase, CREB binding protein (CBP) (Zhang & Bieker, 
1998; Zhang et al., 2001), which in addition to acetylation of EKLF protein can also 
increase acetylation of histones (Blobel, 2002).  Thus, it is highly tempting to speculate 
that Δ221EKLF induces CBP recruitment and increases the acetylation of histone H3 at 
the β-globin promoter in the absence of β-globin transcription. 
 
NF-E2 and GATA-1 have been implicated in mediating H3 acetylation and 
methylation at the β-globin promoter (Kiekhaefer et al., 2002; Kiekhaefer et al., 2004; 
Demers et al., 2007).  Using cell lines, these studies have demonstrated that GATA-1 
induces H3 acetylation (Kiekhaefer et al., 2002) while NF-E2 induces H3K4 
trimethylation at the β-globin promoter (Kiekhaefer et al., 2004; Demers et al., 2007).  In 
contrasts, my study in primary erythroblasts suggests EKLF, and more importantly the 
Δ221EKLF domain, is required and sufficient for H3 acetylation and H3K4 
trimethylation at the β-globin promoter in vivo.  As shown in Figure 3.12, there is modest 
NF-E2 and GATA-1 occupancy at the β-globin promoter in Δ221EKLF and EKLF-null 
cells when compared to wild-type erythroblasts.  However, in contrast to complete loss of 
EKLF, expression of Δ221EKLF results in H3 acetylation and H3K4 trimethylation to a 
level comparable to wild-type in Δ221EKLF erythroblasts.  While it is not possible to 
discount entirely the role of GATA-1 and NF-E2 in histone modifications at the β-globin 
promoter, my results are consistent with the idea that Δ221EKLF is a critical mediator of 
this process.  It is possible the basal levels of GATA-1 and NF-E2 at the β-globin 
promoter require Δ221EKLF to induce H3 acetylation and H3K4 trimethylation in vivo. 
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Nucleosomal remodeling and histone modification are not sufficient for recruitment 
of erythroid-specific transcription factors to the β-globin promoter and activated β-
globin transcription 
 
In the present studies, I show that the level of β-globin transcripts in the 
Δ221EKLF mice is less than 5% of wild-type mice (Figure 3.10).  These results are 
consistent with our previous analysis of Δ221EKLF expressed in an erythroid cell line 
(Brown et al., 2002).  Furthermore, the low levels of β-globin gene transcription despite 
high levels of H3 acetylation and nucleosomal remodeling at the β-globin promoter is 
highly reminiscent of previous studies in mice homozygous for a targeted deletion of the 
LCR (Bender et al., 2000).  These studies have demonstrated that deletion of the LCR 
resulted in a severe reduction of β-globin transcription with concomitant decreased PolII 
occupancy at the β-globin promoter (Bender et al., 2000; Sawado et al., 2003).  However, 
the β-globin promoter remains hyperacetylated and nuclease sensitive in LCR deletion 
and wild-type mice.  Taken together, these observations suggest that nucleosomal 
remodeling and modification of histones are not sufficient to achieve high level β-globin 
transcription in vivo, consistent with lack of LCR recruitment to the promoter.  
Furthermore, the reduced level of PolII occupancy in Δ221EKLF mice is consistent with 
the idea of a long range transfer of PolII from the LCR to the promoter to stimulate 
transcription as has been previously described by Johnson et al. (2001). 
 
GATA-1 and NF-E2 have both been implicated in β-globin gene activation (Kim 
& Bresnick, 2007).  The present studies demonstrate that EKLF is essential for 
recruitment of these factors to the β-globin promoter but not HS2 of the LCR.  Using 
ChIP analysis, both GATA-1 and NF-E2 are recruited normally to HS2 of the LCR in 
Δ221EKLF and EKLF-null erythroblasts.  However, there is significantly lower GATA-1 
and NF-E2 occupancy at the β-globin promoter in Δ221EKLF and EKLF-null 
erythroblasts as compared to wild-type erythroblasts.  My results are novel and unique to 
Δ221EKLF-expressing cells, providing strong support for an essential role for EKLF in 
recruitment of GATA-1 and NF-E2 to the β-globin promoter.  These results are 
contrasted with previous studies that have demonstrated GATA-1 and NF-E2 occupy the 
β-globin promoter in erythroid cells from mice lacking the LCR (Sawado et al., 2003; 
Vakoc et al., 2005), suggesting that recruitment of GATA-1 and NF-E2 to the β-globin 
promoter occur independent of the LCR.  The results in the present study are consistent 
with two possible mechanisms of transcriptional factor recruitment to the β-globin 
promoter.  The first mechanism proposes that recruitment of GATA-1 and NF-E2 to the 
β-globin promoter is EKLF-dependent, requiring a larger amino terminal domain of 
EKLF.  An alternative mechanism is that GATA-1 and NF-E2 are first recruited to the β-
globin LCR (EKLF-independent) and then transferred to the β-globin promoter (EKLF-
dependent).  Studies to examine LCR/β-globin promoter interaction would provide 
additional insights into the mechanism of transcriptional factor recruitment to the β-
globin promoter to stimulate gene transcription.  
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A model for Δ221EKLF in β-globin promoter remodeling 
  
Although in vitro and cellular studies have analyzed the coordinated recruitment 
of transcription factors and coactivators required for high level β-globin transcription, 
much knowledge remains to be gained from studying EKLF-mediated chromatin 
remodeling and β-globin transcription in vivo.  The results from the present studies in 
Δ221EKLF mice indicate that chromatin remodeling and histone modifications are not 
sufficient to achieve high-level β-globin transcription in vivo.  Furthermore, these studies 
suggest that Δ221EKLF is sufficient for β-globin promoter remodeling but additional 
amino terminal sequences are necessary for recruitment of transcriptional factors to the 
promoter.  A proposed model for the role of Δ221EKLF in promoter remodeling is shown 
in Figure 3.13.  First, H3 acetylation and H3K4 trimethylation at HS2 of the β-globin 
LCR occurs independent of EKLF. Furthermore, GATA-1, NF-E2, and PolII are 
recruited normally in the absence of EKLF.  In contrast, these events at the β-globin 
promoter are EKLF-dependent.  Similar to the observation in wild-type erythroblasts, 
expression of Δ221EKLF results in an open chromatin configuration with histone 
modifications consistent with an active gene promoter.  However, recruitment of GATA-
1, NF-E2, and PolII to stimulate transcription at the β-globin promoter requires additional 
amino terminal sequences of EKLF not included in the Δ221EKLF domain.  In contrast, 
the β-globin promoter in EKLF-null erythroblasts remains in a closed chromatin 
configuration consistent with a repressed β-globin promoter.  It is unclear at this juncture 
what role Δ221EKLF plays in LCR/β-globin promoter interaction.  Thus, further 
dissection of the role of Δ221EKLF in modulation of the LCR/β-globin promoter 
interaction and recruitment of other factors at the β-globin promoter will provide 
additional fundamental insights into EKLF-mediated chromatin remodeling and β-globin 
transcription in vivo. 
Figure 3.13. Models of β-globin promoter remodeling in erythroid cells.  Histone 
modifications and recruitment of GATA-1, NF-E2, and PolII to the β-globin LCR does 
not require EKLF.  In contrast, the events at the β-globin promoter are EKLF-dependent.  
(A) In wild-type erythroblasts, EKLF induces H3 hyperacetylation and H3K4 
trimethylation.  Transcriptional factors (GATA-1, NF-E2, PolII) are recruited to the β-
globin promoter to stimulate β-globin gene transcription.  (B) In Δ221EKLF-expressing 
erythroblasts, Δ221EKLF alone is sufficient to induce H3 hyeracetylation and H3K4 
trimethylation.  However, additional amino terminal sequences of EKLF are required for 
recruitment of GATA-1, NF-E2, and PolII to stimulate β-globin gene transcription.  (C) 
In the absence of EKLF, the β-globin promoter remains in a closed chromatin 
configuration consistent with a repressed gene promoter. 
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CHAPTER 4: EXPRESSION OF Δ221EKLF RESULTS IN ALTERED 
ERYTHROID MATURATION AND BLOCKED MEGAKARYOCYTIC 
EXPANSION 
 
 
INTRODUCTION 
 
Hematopoiesis is a complex developmental process in which hematopoietic stem 
cells (HSCs) continuously generate all blood cell lineages.  The current model of 
hematopoeisis proposes that HSCs proceed through multiple steps of committed 
progenitors to give rise to mature blood cells in each lineage (Weissman et al., 2001, 
Orkin & Zon, 2008) (see Figure1.1 in Chapter 1).  This model is based historically on the 
results from in vitro assays developed to quantify multi-potential progenitors and lineage-
restricted progenitors of bone marrow cells cultured in semi-solid media (Nakorn et al., 
2003).  Erythroid and megakaryocytic lineages are believed to be derived, at least in part, 
from a common bipotential progenitor.  Termed the megakaryoctye-erythrocyte 
progenitor (MEP) this cell generates unipotential erythroid or megakaryocytic 
progenitors (Debili et al., 1996; Nakorn et al., 2003). These precursors express many 
hematopoietic transcription factors that are essential for both erythropoiesis and 
megakaryopoiesis.  Although many of these factors are essential, the precise mechanism 
of action/pathways directing the fate of the MEP towards one lineage over another 
remains obscure. 
 
Two factors, EKLF and Fli-1, have emerged in recent studies as key players in the 
erythroid-megakaryocytic differentiation switch.  Both are expressed in the bipotential 
MEP (Frontelo et al., 2007); however, the levels of these genes are differentially 
expressed depending on the commitment fate of the MEP.  During early MEP 
differentiation, EKLF and Fli-1 have contrasting levels of expression.  In erythroid 
progenitors, EKLF expression is high, whereas in megakaryocytic progenitors Fli-1 
expression is more than 60-fold greater compared with erythroid progenitors (Frontelo et 
al., 2007).   
 
EKLF and Fli-1 protein-protein interactions have also been noted (Starck et al., 
2003).  These in vitro studies suggest that EKLF and Fli-1 do not inhibit each other’s 
binding activity and Fli-1 mediated activation of a megakaryocytic gene promoter 
construct (i.e., GpIX) can be repressed by EKLF zinc finger domain alone (Starck et al., 
2003).  Supporting these observations, Bouilloux et al. (2008) have shown that knock-
down of EKLF by shRNA results in an increase in megakaryocytic gene expression in 
differentiated MEL cells.  Furthermore, ChIP analysis revealed increased acetylation of 
histone H3 and occupancy of PolII, GATA-1, and Fli-1 at megakaryocytic gene 
promoters with EKLF knock-down in MEL cells.  By contrast, studies by Siatecka et al. 
(2007) propose that sumoylation of lysine 74 of EKLF is critical for repression of 
megakaryopoiesis.  Taken together, these studies suggest three potential, and non-
exclusive, models of EKLF-mediated repression of megakaryopoiesis (Figure 4.1): (i) 
EKLF inhibits Fli-1 gene transcription; (ii) EKLF inhibits Fli-1 binding to its target 
promoters (i.e. GpIX) by protein-protein interaction; and (iii) EKLF binds to Fli-1- 
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• EKLF represses Fli-1 promoter activity in a 
transient construct in K562 cells (Frontelo et al., 
2007).
• Fli-1 Ets domain interacts with EKLF zinc 
finger DNA binding domain (Starck et al., 2003).
•EKLF inhibits Fli-1-mediated activation of 
transient GpIX promoter construct (Starck et al., 
2003).
•EKLF knock-down in cell lines increases Fli-1 
occupancy at megakaryocytic gene promoters 
(including GpIX and Fli-1) (Bouilloux et al., 
2008).
• EKLF represses megakaryocytic gene 
expression in MEL cells (Bouilloux et al., 2008).
•EKLF knock-down in cell lines increases PolII 
occupancy and acetylation of histone H3 at the 
megakaryocytic gene promoters (Bouilloux et 
al., 2008).
 
 
 
 
Figure 4.1.  Potential models of EKLF-mediated repression of megakaryopoiesis.  Shown here is a simplified diagram 
depicting three possible mechanisms for EKLF-mediated repression of megakaryopoiesis with support for each model from the 
current literature.  (1) EKLF inhibits Fli-1 gene transcription.  (2) EKLF inhibits Fli-1 binding to its targets (i.e. GpIX) by 
protein-protein interaction. (3) EKLF binds to Fli-1-targeted regulatory sequences and blocks Fli-1-medication activation. 
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targeted regulatory sequences and blocks Fli-1 mediated activation. 
 
While previous studies have provided significant insights into the role of EKLF in 
the erythroid-megakaryocytic differentiation program, it is important to note that these 
studies have been performed in cell lines and may not recapitulate events in vivo.  The 
studies in this chapter seek to expand our current knowledge on the role of EKLF in MEP 
differentiation utilizing the newly generated mice expressing Δ221EKLF.  I report here 
that, similar to complete loss of EKLF, expression of Δ221EKLF results in a block of 
terminal erythroid differentiation at the proerythroblast stage, due in part, to decreased 
expression of genes essential for erythroid development.  However, proliferation of 
erythroid progenitors is unaltered when compared to wild-type erythroblasts.   
 
In contrast, expression of Δ221EKLF inhibits the expansion of megakaryocytic 
progenitors observed with complete loss of EKLF.  Molecular analysis of the Fli-1 
promoter is consistent with the idea that inhibition of megakaryocytic expansion is 
achieved, in part, by Δ221EKLF repression of Fli-1 through recruitment of a Sin3A-
containing repressor complex.  Taken together, my results suggest that the Δ221EKLF 
domain alone is sufficient for EKLF-dependent inhibition of megakaryocytic 
differentiation in vivo.  
 
 
MATERIALS AND METHODS 
 
 
Mice 
 
EKLF-null mice were previously generated via gene targeting by Perkins et al. 
(1995).  Δ221EKLF mice were generated via gene targeting as described in Chapter 2 of 
this dissertation.  Genotyping of wild-type, EKLF-null, Δ221EKLF embryos were 
performed by PCR method as described in Chapter 3. 
 
 
Colony-forming assays 
 
Fetal livers cells were obtained by passing E14.5 fetal liver through a 70 µm cell 
strainer in D10 (DMEM + 10% FBS).  To evaluate the erythroid colonies (burst forming 
units- erythroid; BFU-E), granulopoietic colonies (colony forming units-granulocyte-
macrophage; CFU-GM), and colonies containing multiple lineages of cells (colony-
forming unit-granulocyte-erythroid-monocyte-megakaryocyte; CFU-GEMM), fetal liver 
cell suspensions were plated (1 x 104 cells/mL) on methylcellulose medium (MethoCult 
3434; StemCell Technologies) supplemented with stem cell factor, IL-3, IL-6, and 
erythropoietin as recommended by the manufacturer. Cells were plated in 35mm dishes 
and maintained at 37°C in a humidified atmosphere at 5% CO2 for 10–12 days.  The 
colonies were then counted under an inverted microscope and expressed as average 
number of CFU colonies per culture. Colonies were identified as described in the 
technical manual for Mouse Colony-Forming Assay using Methocult 
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(http://www.stemcell.com/technical/28405_methocult%20M.pdf).  
 
To evaluate the colony forming units-megakaryocytes (CFU-Mk), fetal liver cell 
suspensions were plated (1 x105 cells/mL) on collagen medium (Megacult-C, StemCell 
Technologies) containing collagen (1.1 mg/mL), recombinant thrombopoietin (50 ng/Ml), 
recombinant IL-3 (10 ng/mL), recombinant IL-6 (20 ng/mL), and recombinant IL-11 (50 
ng/mL). Cells were plated in double chamber slides in a 100 mm petri dish and 
maintained at 37°C in a humidified atmosphere at 5% CO2 for 14 days as recommended 
by the manufacturer (StemCell Technologies). The slides were fixed with methanol-
acetone solution after removing the double chamber and stored at -20°C until staining 
could be performed.   Histochemical staining was performed with acetylthiocholiniode 
(Sigma). The colonies were then counted under an inverted microscope and expressed as 
average number of CFU-Mk colonies per culture. CFU-Mk colonies were identified as a 
group of 3 to 50 megakaryocytes per colony with acetyl cholinesterase activity, evident 
by brown granules in the cytoplasm. Each experiment was performed a minimum of four 
times, and the data were analyzed using a Student t-test. 
 
 
FACS analysis  
 
Fetal livers from E14.5 embryos were passed through a 23-gauge needle three 
times, filtered through a 70 μM cell strainer, washed with D10 medium (DMEM + 10% 
FBS), and submitted on ice to the Flow Cytometry and Cell Sorting Shared Resource 
Center at St Jude Children’s Research Hospital.  Cells were washed in PBS + 5% FBS 
and incubated on ice in human gamma gobulin solution (100 mg/mL in PBS-5%) for 
blocking of nonspecific staining.  Cells were then washed in PBS-5% and incubated on 
ice for 30 min with 0.5 μg of phycoerythrin (PE)-conjugated anti-mouse CD71 and 
allophycocyanin (APC)-conjugated anti-mouse TER119 antibodies (BD PharMingen).  
Results were analyzed using Flow-Jo software (Tree Star).  
 
 
Globin gene expression by real time RT-PCR 
 
Real time RT-PCR to analyze the expression of EKLF target genes were 
performed as described in Chapter 3.  The primers used for real time RT-PCR are shown 
in Appendix Table A.5.  Each sample was run in duplicate with at least five independent 
experiments performed.  
 
 
Chromatin immunoprecipitation assays 
 
ChIP assay was performed as described in Chapter 3 with addition of anti-Sin3A 
(Santa Cruz, sc-994x) antibody.  Primers for ChIP analysis at Fli-1 promoter are: 
forward: CGTGGACCCCGTCATTGTT and reverse: 
GCACTGCGCACACAGGATACT (Frontelo et al., 2007).  Primers for β-globin 
promoter are the same as those described in Chapter 3. 
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RESULTS 
 
 
Expression of Δ221EKLF alters erythroid differentiation and inhibits expansion of 
megakaryocytic progenitors  
 
To assess the maturation and differentiation potential of fetal liver cells from 
Δ221EKLF embryos, I used a flow cytometry assay that allows quantitative evaluation of 
erythroid differentiation on the basis of expression of the erythroid-specific TER119 and 
nonerythroid-specific CD71 (transferrin receptor) cell surface markers.  Cells were flow 
sorted, and a density plot of relative logarithmic fluorescence units for CD71-expressing 
versus TER19-expressing was generated (Figure 4.2A).  According to previous studies, 
cells are defined by a characteristic pattern of CD71 and TER119 staining such that 
CD71medTER119low cells are predominantly progenitor cells,  CD71highTER119low are 
early basophilic proerythroblasts, CD71highTER119high are early and late basophilic 
erythroblasts, CD71medTER119high are chromatophilic and orthochromatophilic 
erythroblasts,  and CD71lowTER119high are late orthochromatophilic erythroblasts and 
recticulocytes (Socolovsky et al., 2001; Zhang et al., 2003).  Using this assay, I validated 
previous studies that demonstrated TER119 was absent in EKLF-null fetal liver cells 
while CD71 expression at the cell surface was normal (Figure 4.2A, top panels) (Hodge 
et al., 2005), suggesting that loss of EKLF resulted in a block of erythroid maturation at 
the proerythroblast stage (Pilon et al., 2008).  As shown in Figure 4.2A (bottom panels), a 
comparable pattern of CD71/TER119 staining was observed in fetal liver cells from 
Δ221EKLF embryos of a similar chronology.  Fetal liver cells from EKLF heterozygous 
and Δ221EKLF heterozygous littermates demonstrated proper execution of the terminal 
erythroid differentiation program.  Thus, it appears that expression of the Δ221EKLF 
domain alone is insufficient for execution of the terminal erythroid differentiation 
program in vivo, resulting in a block at an early stage of erythroid differentiation.  
 
A block in terminal erythroid differentiation as a consequence of Δ221EKLF 
expression led me to speculate that Δ221EKLF affected the proliferation of 
hematopoietic progenitors in vivo.  To quantify the number of erythroid colonies, fetal 
liver cells from wild-type, Δ221EKLF, and EKLF-null embryos were cultured in a 
methylcellulose-based medium supplemented with cytokines to promote the growth of 
BFU-E, CFU-GM, and CFU-GEMM colonies.  As shown in Figure 4.2B, there was no 
statistical difference in the number of BFU-e and CFU-GM colonies cultured from fetal 
liver of wild-type, Δ221EKLF, and EKLF-null embryos.  Analysis of the BFU-E colonies 
revealed colonies of similar size (Appendix Figure A.3).   These observations are in 
agreement with previous studies in EKLF-null mice (Perkins et al., 1995), consistent with 
the idea that expression of Δ221EKLF does not affect the proliferation of erythroid 
progenitors.  On the other hand, these studies revealed comparable numbers of CFU-
GEMM colonies in Δ221EKLF and wild-type animals.  In contrast, there is an expansion 
of CFU-GEMM colonies in EKLF-null animals.  This observation was quite interesting 
given that recent studies by Frontelo et al. (2007) and Bouilloux et al. (2008) proposed a 
novel role for EKLF in megakaryopoiesis.  Subsequently, I speculated whether the 
Δ221EKLF domain alone is sufficient to inhibit the expansion of megakaryocytic  
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Figure 4.2.  Effects of Δ221EKLF expression on terminal erythroid differentiation 
and proliferation of fetal liver progenitor cells. (A) Fluorescence-activated cell sorting 
analysis of E14.5 fetal liver cells from wild-type, EKLF-null heterozygous and EKLF-
null embryos (top panel).  In a separate experiment, FACS analysis of E14.5 fetal liver 
from wild-type, Δ221EKLF heterozygous, and Δ221EKLF embryos.  Cells were stained 
with anti-CD71 and anti-TER119 antibodies. (B) Analysis of hematopoietic colony-
forming cells in E14.5 fetal liver cells from wild-type, Δ221EKLF, and EKLF-null 
embryos.  Data shown are averages of at least three independent experiments performed 
in duplicate (mean ± SEM).  NS = not significant; p-value for significant difference 
shown.   
 73
progenitors observed with complete loss of EKLF. 
  
 
Δ221EKLF alters expression of non-β-globin-like erythroid-specific genes 
 
To determine if the failure of terminal erythroid differentiation in Δ221EKLF 
mice was due in part to lack of expression of non-β-globin erythroid-specific genes, I 
examined the expression of genes that have been shown to be direct targets of EKLF 
activation and those that are putative targets (Figure 4.3).  Real time RT-PCR analysis 
revealed that expression of known EKLF target genes, Epb4.9 (Hodge et al., 2005) 
ankyrin and band 3 (Nilson et al., 2006), BKLF (Funnell et al., 2006), and AHSP (Pilon 
et al., 2006) were significantly reduced in fetal liver erythroblasts from Δ221EKLF 
embryos as compared to wild-type erythroblasts of similar chronology (Figure 4.3A). 
Similarly, expression of Δ221EKLF could not rescue high level expression of genes 
involved in heme biosynthesis (Figure 4.3B).  Interestingly, these genes have not been 
shown to be direct EKLF target genes. These results are consistent with earlier 
observations at the β-globin locus (see Figure 3.10), confirming that a larger amino 
terminal domain of EKLF is required for EKLF-dependent gene transcription in vivo.   
 
 
A role for Δ221EKLF in megakaryopoiesis and regulation of Fli-1 
 
While it is interesting that Δ221EKLF fails to rescue expression of other non-β-
globin-like erythroid-specific genes in vivo and the local chromatin structure at these 
gene promoters remains to be analyzed, I have decided to shift my focus to explore 
further the novel observation that Δ221EKLF inhibits expansion of megakaryocytic 
progenitors in vivo.  Around the time that I made this observation in Δ221EKLF mice, 
two interesting studies utilizing cell lines concluded that EKLF represses megakaryocytic 
differentiation, at least in part, through Fli-1 repression (Frontelo et al., 2007; Bouilloux 
et al., 2008).  Extending these studies, Siatecka et al. (2007) proposed a critical role for 
the sumoylation of lysine 74 in repression of megakaryopoiesis in a transgenic mouse 
model.  These studies are reminiscent of earlier studies in which overexpression of EKLF 
transgene resulted in reduced platelet counts in adult mice (Tewari et al., 1998).  While 
these studies have significantly expanded our knowledge on the role of EKLF in 
megakaryopoiesis, they have all been studied by overexpression of EKLF protein.  Thus, 
understanding EKLF repression of Fli-1 is of crucial importance, and the Δ221EKLF 
mice provide a unique opportunity in which to explore this novel role for EKLF in vivo. 
 
To confirm that the blocked expansion of CFU-GEMM, a mixed cell colony 
containing granulocyte-erythrocyte-monocyte-megakaryocyte progenitors, was indeed 
due to inhibition of megakaryocytic progenitors, I performed a more specific assay to 
identify only CFU-MK by staining for acetylcholinesterase activity.  Acetylcholinesterase 
activity is a marker for murine megakaryocytes (Saleque et al., 2002) and is evident by 
dark-brown to dark-red granules.  As expected, expression of Δ221EKLF in vivo, resulted 
in fewer megakaryocytic colonies as compared to complete loss of EKLF (Figure 4.4).  
More importantly, the number of MK progenitors in Δ221EKLF fetal liver is equivalent. 
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Figure 4.3. Altered pattern of erythroid-specific gene expression in Δ221EKLF fetal 
liver erythroblasts.  cDNA was synthesized from RNA extracted from fetal liver of 
E14.5 wild-type, Δ221EKLF, and EKLF-null embryos and analyzed by real time RT-
PCR.  (A) Expression level of genes previously shown to be direct targets of EKLF-
mediated activation. (B) Expression level of genes involved in the heme biosynthesis and 
not known to be direct targets of EKLF-mediated activation.  Data shown are averages of 
at least five independent experiments performed in duplicate (mean ± SEM).   
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 to that found in the wild-type fetal liver, consistent with the idea that expression of 
Δ221EKLF alone is sufficient to restore megakaryocytic progenitors to wild-type levels.  
Similarly, the MK colonies obtained from Δ221EKLF fetal liver are similar in 
appearance and size to those from wild-type fetal liver (Figure 4.4, bottom panel).  
Together, these observations are consistent with the idea that expression Δ221EKLF 
alone is sufficient to block the expansion of MK progenitors observed with complete loss 
of EKLF 
 
To explore the role of Δ221EKLF in regulating the Fli-1 promoter, real time RT-
PCR was used to determine the expression of Fli-1 in fetal liver erythroblasts derived 
from wild-type, Δ221EKLF, and EKLF-null embryos (Figure 4.5).   This was contrasted 
with expression of β-globin in the same samples (Figure 4.5A).  As shown in Figure 
4.5B., there was no statistically significant difference in Fli-1 expression as measured by 
real time RT-PCR.  This observation did not agree with previous expression array 
analysis (Frontelo et al., 2007) and my earlier findings that expansion of the MK 
progenitors observed with complete loss of EKLF was inhibited by Δ221EKLF 
expression (see Figure 4.2B).  It is also possible that I did not observe repression of Fli-1 
as expected because I had not analyzed the mRNA levels in the context of MK progenitor 
cells or for other reasons (see Discussion below).  To test if Fli-1 levels were 
differentially expressed during early murine development, Fli-1 mRNA was determined 
in erythroid cells derived from yolk sac of E9.5 embryos.  Interestingly, a 2-fold decrease 
in Fli-1 mRNA was noted in Δ221EKLF and wild-type yolk sac cells (Figure 4.5C) when 
compared with EKLF-null cells, although the difference in expression only approached 
statistical significance (p-value = 0.07).   
  
To further explore the role of Δ221EKLF in regulation of Fli-1, chromatin 
immunoprecipitation (ChIP) assay was utilized to analyze Δ221EKLF binding, PolII 
occupancy, and histone H3 acetylation at the Fli-1 promoter contrasting these 
observations with studies of factor occupancy at the β-globin promoter (Figure 4.6A-C).  
Analysis of factor binding at the promoters revealed a distinct pattern of binding.  
Δ221EKLF occupied the β-globin and Fli-1 promoters in a similar fashion (Figure 4.6A), 
an observation consistent with previous data for wild-type EKLF (Zhou et al., 2006; 
Frontelo et al., 2007).  While binding of PolII protein at the β-globin promoter was 
enriched in wild-type fetal liver erythroblasts, there was minimal PolII binding noted in 
Δ221EKLF and EKLF-null erythroblasts (Figure 4.6B, left panel).  By contrast, there was 
a 2-fold decrease in PolII recruitment at the Fli-1 promoter in wild-type and Δ221EKLF 
erythroblasts (Figure 4.6B, right panel), consistent with the idea that Fli-1 levels are 
reduced in these cell types.  Similarly, the β-globin promoter is acetylated to comparable 
levels in wild-type and Δ221EKLF erythroblasts (Figure 4.6C, left panel).  By contrast, 
the Fli-1 promoter is hypoacetylated in these cell types and hyperacetylated in EKLF-null 
cells (Figure 4.6C, right panel). 
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Figure 4.4. Blocked expansion of megakaryocytic progenitors in Δ221EKLF mice. 
Analysis of megakaryocytic colony-forming cells (CFU-MK) in E14.5 fetal liver cells 
from wild-type, Δ221EKLF, and EKLF-null embryos.  Top panel: frequency of CFU-MK 
colonies counted per culture condition (1 x 10^5 cells plated). Cells were plated in double 
chamber slides, maintained at 37°C in a humidified atmosphere at 5% CO2 for 14 days, 
after which slides were fixed and stained for acetylcholinesterase activity, and CFU-MK 
counted.  Data shown are averages of at least three independent experiments performed in 
duplicate (mean ± SEM).  NS = not significant; p-value for significant difference shown. 
Bottom panel: photographs of representative CFU-MK colonies from wild type, 
Δ221EKLF, and EKLF-null fetal liver cells after staining.  Acetylcholinesterase is 
evident by the dark-brown granules. 
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Figure 4.5.  Differential expression of β-globin and Fli-1 gene in Δ221EKLF 
expressing cells. cDNA prepared from RNA extracted from E14.5 fetal liver (FL) and 
E9.5 yolk sac (YS) of wild-type, Δ221EKLF, and ELF-null embryos were analyzed by 
real time RT-PCR for (A) β-globin mRNA, (B) Fli-1 mRNA in cells derived from fetal 
liver, and (C) Fli-1 mRNA in cells derived from yolk sac. Data shown as average from at 
least five independent experiments performed in duplicate (mean ± SEM).   p-value 
shown for significant difference.  NS = not significant. 
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Figure 4.6.  Distinct regulation of β-globin and Fli-1 promoters in Δ221EKLF fetal 
liver erythroblasts.  ChIP assays were utilized to examine factor binding at the β-globin 
and Fl-1 promoters, respectively.  (A) Binding of Δ221EKLF at the β-globin and Fli-1 
promoters in fetal liver erythroblasts from E13.5 Δ221EKLF embryos was detected by  
anti-HA-specific antiserum.   (B)  Occupancy of total PolII at the β-globin and Fli-1 
promoters in fetal liver erythroblasts from E13.5 wild-type, Δ221EKLF, and EKLF-null 
embryos. (C) Acetylation of Histone H3 at the β-globin and Fli-1 promoters in fetal liver 
erythroblasts from E13.5 wild-typeΔ221EKLF, and EKLF-null embryos.  Data shown as 
averages from at least five independent experiments performed in duplicate (mean ± 
SEM).   p-value shown for significant difference.  NS = not significant.   
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A repressor complex is recruited to the Fli-1 promoter in Δ221EKLF cells 
  
To explore the mechanism by which EKLF and Δ221EKLF might regulate Fli-1 
transcription in vivo, ChIP assays were utilized to examine the recruitment Sin3A to the 
Fli-1 promoter.  Previous studies have shown that EKLF exhibits transcriptional 
repression properties by interacting with Sin3A through its zinc finger DNA binding 
domain (Chen & Bieker, 1996; Chen & Bieker, 2004).  Sin3A binding at the Fli-1 
promoter was increased 2-fold in fetal liver erythroblasts derived from wild-type and 
Δ221EKLF embryos as compared to EKLF-null erythroblasts (Figure 4.7, right panel), 
thus suggesting that the Fli-1 promoter is repressed.  In contrast, no significant binding of 
Sin3A was noted at the β-globin promoter (Figure 4.7, left panel), consistent with the 
idea that a repressor complex has no role in regulation of the β-globin gene.  In summary, 
these results suggest that EKLF-mediated repression of Fli-1 is achieved in part by 
recruitment of a Sin3A-containing complex and that expression of Δ221EKLF alone is 
sufficient for this recruitment.   
 
 
DISCUSSION 
 
Studies in this chapter suggest that expression of Δ221EKLF alone is insufficient 
to support erythroid terminal differentiation; however, this domain of EKLF is sufficient 
to block expansion of megakaryocytic progenitors in vivo.   This novel observation in 
mice expressing Δ221EKLF confirms the importance of generating these animals as 
valuable tools to elucidate the role of EKLF-mediated activation and repression at 
erythroid- and megakaryocytic-specific gene loci in vivo. 
 
 
Failure of erythroid differentiation in Δ221EKLF-expressing cells 
 
EKLF was first characterized as a transcriptional activator that modulated β-
globin gene expression during erythropoiesis.  Subsequent studies extended the targets of 
EKLF-mediated activation to include α-hemoglobin stabilizing protein (AHSP), 
cytoskeleton proteins (ankyrin, Epb4.9), and transcription factors (BKLF) (Pilon et al., 
2006; Nilson et al., 2006; Funnell et al.,2007).  Understandably, these are critical genes 
for erythroid development and differentiation.  The studies in this chapter not only 
confirm that EKLF is essential for erythroid gene expression and terminal erythroid 
differentiation, but also a domain of EKLF (Δ221EKLF) that is capable of chromatin 
remodeling (see Chapter 3) is insufficient to fulfill this role in vivo.  Indeed, expression of 
Δ221EKLF in a whole animal model results in a block of terminal erythroid 
differentiation similar that observed in complete loss of EKLF.  However, proliferation of 
erythroid progenitors is unaffected by expression of Δ221EKLF in vivo.   Furthermore, 
expression of Δ221EKLF fails to rescue the expression of ankyrin, band3, Epb4.9, BKLF,  
AHSP, and all seven genes involved in heme biosynthesis to wild-type levels.  It is worth 
noting that none of the heme biosynthetic genes are known direct targets of EKLF.  It 
would be interesting to speculate on the chromatin structure at these gene promoters; 
however, studies to examine the DNase I sensitivity at the gene promoters are ongoing in  
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Figure 4.7. Recruitment of a Sin3A-containing repressor complex.  ChIP analysis was 
performed in fetal liver erythroblasts from E13.5 wild-type, Δ221EKLF, and EKLF-null 
embryos.  Occupancy of Sin3A was determined at Fli-1 promoter contrasted with 
occupancy at β-globin promoter.  Data shown as averages from at least three independent 
experiments performed in duplicate (mean ± SEM).  p-value shown for significant 
difference.  NS = not significant.   
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our laboratory and should provide significant insights into the role of Δ221EKLF at non-
β-globin erythroid-specific gene loci.  While it is interesting that Δ221EKLF is 
insufficient to rescue non-β-globin-like erythroid gene expression examined in the 
present study, the question remains if there are genes that require only the chromatin 
remodeling domain of EKLF for high-level expression in vivo.  Gene expression profiling 
studies utilizing the Δ221EKLF mice are ongoing in our laboratory to address this 
hypothesis. 
 
 
Δ221EKLF regulates Fli-1 gene and inhibits expansion of megakaryocytic 
progenitors in vivo  
 
The most compelling conclusion of the studies presented in this chapter is that 
expression of Δ221EKLF is sufficient to repress megakaryocytic differentiation in vivo.  
This result is particularly interesting given that studies in the previous chapter have 
shown that Δ221EKLF mutant protein is expressed at a lower level than wild-type EKLF 
protein.  Despite this caveat, my studies show that Δ221EKLF protein is expressed at a 
sufficient level to repress megakaryopoiesis in vivo.  This conclusion is supported by 
results from colony-forming assays demonstrating equivalent numbers of megakaryocytic 
progenitors in fetal liver from Δ221EKLF and wild-type animals (Figure 4.4).  
Furthermore, chromatin immunoprecipitation assays show that expression of Δ221EKLF 
increases Δ221EKLF binding to the Fli-1 promoter and decreases PolII occupancy and 
acetylation of histone H3 at the Fli-1 promoter (Figure 4.6A-C).  Given these results, I 
would have expected Fli-1 mRNA levels to be reduced in fetal liver erythroblasts from 
E14.5 wild-type and Δ221EKLF embryos as compared to EKLF-null erythroblasts; 
however, real time RT-PCR analysis showed no significant difference in Fli-1 mRNA 
levels (Figure 4.5B).  Expression arrays between EKLF wild-type and EKLF-null fetal 
liver cells demonstrate only a 2.5-fold up-regulation of Fli-1 in the absence of EKLF 
(Frontelo et al., 2007).  By contrast, it is possible that the lineage fate decision has 
already been determined prior to E14.5 of murine development. Thus, Fli-1 mRNA level 
has been measured in cells that have already committed to the erythroid lineage in 
Δ221EKLF homozygous and wild-type animals.  In a similar manner, cells lacking EKLF 
are driven towards the megakaryocytic lineage.  As a result, the level of Fli-1 at this stage 
of murine development may not play a role in the lineage fate decision.  To reconcile this 
discrepancy, I have also analyzed the levels of Fli-1 mRNA in cells derived from yolk sac 
of E9.5 of wild-type, Δ221EKLF, and EKLF-null embryos (Figure 4.5C).  During this 
stage of murine development, the yolk sac is the source of all hematopoietic progenitor 
cells (Palis et al., 1999; Lux et al., 2008).  Moreover, hematopoietic progenitor cell types, 
including erythrocyte and megakaryocyte progenitors, can be cultured from E9.5 yolk sac 
cells (Rampon & Huber, 2003).  Indeed, I found that Fli-1 mRNA was decreased 2-fold 
in erythroid cells derived from E9.5 Δ221EKLF and wild-type yolk sac.  Thus, these 
results are consistent with the idea that the level of Fli-1 is important during early murine 
development in order to influence lineage fate decisions. 
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Δ221EKLF uniquely inhibits Fli-1 by recruitment of a Sin3A-containing corepressor 
complex  
 
Previous studies have shown that EKLF can function as a transcriptional repressor 
through its zinc finger DNA binding domain, which can recruit Sin3A and HDAC1 (Chen 
& Bieker, 1996; Chen & Bieker, 2004) and more recently through sumoylation of lysine 
74, which can then recruit the Mi-2β component of the NuRD repressor complex 
(Siatecka et al., 2007).   Interestingly, in contrast to wild-type EKLF, expression of a 
K74R EKLF mutant that cannot be sumoylated cannot repress megakaryopoiesis in 
transgenic mice (Siatecka et al., 2007).  Several new results obtained from my studies 
directly challenge the latter observation.  First, I show that expression of Δ221EKLF is 
sufficient to repress megakaryocytic differentiation in vivo in a similar manner to wild-
type EKLF (Figure 4.4). Thus, this indicates that sumoylation of lysine 74 is not required 
for EKLF-mediated repression of megakaryopoiesis in vivo (Siatecka et al., 2007).  
Furthermore, my studies utilized a model in which the Δ221EKLF protein is expressed 
from the endogenous EKLF promoter under the control of cis regulatory elements.  In 
contrast, studies by Siatecka et al. (2007) were performed in a transgenic murine model 
in which the mutant protein was over-expressed under the control of the PF4-gene 
promoter (Siatecka et al., 2007), which may not recapitulate the events in vivo precisely.  
The most obvious pitfall is that proteins expressed from heterologous promoters may not 
be expressed in a tissue- and developmentally-specific manner as the endogenous protein.  
My studies also found that Sin3A occupancy is increased at the Fli-1 promoter in 
Δ221EKLF and wild-type erythroblasts (Figure 4.7). These observations are in contrast to 
studies demonstrating that the NuRD repressor complex is involved in EKLF-mediated 
repression of megakaryopoiesis (Siatecka et al., 2007).  Sin3A is not part of the NuRD 
complex (Downes et al., 2000).  Taken together, my results provide strong support for the 
Δ221EKLF domain in EKLF-mediated repression of megakaryocytic differentiation 
through recruitment of a Sin3A-containing repressor complex. 
 
Three potential models of EKLF-mediated repression of megakaryopoiesis can be 
derived from review of the recent literature (see Introduction above; Figure 4.1).  
Although support exists for each model, the precise mechanism by which EKLF 
represses megakaryocytic differentiation remains to be fully explored.  Based on my 
current studies, I propose a modified model in which EKLF represses megakaryopoiesis, 
at least in part, by inhibition of Fli-1 through recruitment of a Sin3A-containing repressor 
complex (Figure 4.8).  The Δ221EKLF domain alone is sufficient for this recruitment.  At 
this time, studies in our laboratory are ongoing to address the other two potential models 
in the context of Δ221EKLF.  We have planned experiments to explore expression of 
megakaryocytic genes (i.e. GpIX) in vivo and occupancy of Δ221EKLF protein and 
additional factor binding at these gene promoters.  Furthermore, we propose studies to 
confirm EKLF and Fli-1 interaction in vivo by purifying Δ221EKLF protein complexes. 
Regardless of the exact mechanism of EKLF-mediated repression of megakaryopoiesis, 
the Δ221EKLF mice have proven to be an indispensable model in which to explore this 
question in vivo. 
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Fli-1
X
Fli-1
Sin3A
Complex
1
3
2
•Δ221EKLF binds to the Fli-1 promoter.
•Expression of Δ221EKLF alone is sufficient to 
repress megakaryocytic differentiation in vivo.
• Expression of Δ221EKLF reduces occupancy 
of PolII and acetylation of histone H3 at Fli-1 
promoter.
• A Sin3A-containing repressor complex is 
recruited to the Fli-1 promoter.  The Δ221EKLF 
domain is necessary and sufficient for this 
recruitment.
?
?
 
 
 
Figure 4.8. Modified potential models of Δ221EKLF-mediated repression of megakaryopoiesis.  Shown here is a 
simplified diagram depicting three possible mechanisms for EKLF-mediated repression of megakaryopoiesis.  Results obtained 
from the current studies in my dissertation support the model in which EKLF inhibits Fli-1 gene transcription through 
recruitment of a Sin3A-containing repressor complex.  The Δ221EKLF domain alone is sufficient for this repression in vivo.  It 
is unclear at this juncture how Δ221EKLF affects the other two potential models of EKLF-mediated repression of 
megakaryopoiesis.  Studies are ongoing to address these questions. 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
The studies presented in this dissertation contribute to our understanding of the 
role of the zinc finger transcription factor EKLF or erythroid Krüppel-like factor in 
erythroid and megakaryocytic differentiation.  I have generated mice expressing an amino 
truncation mutant of EKLF (Δ221EKLF).  This domain of EKLF has been shown to 
retain full and appropriate chromatin remodeling activity of wild-type EKLF in vivo. 
However, expression of this domain is insufficient to rescue high-level β-globin gene 
transcription in vivo.  In contrast, expression of Δ221EKLF is sufficient to inhibit 
expansion of megakaryocytic progenitors observed with a complete loss of EKLF.  Thus, 
the studies described in the preceding chapters provided novel and insightful knowledge 
on the role of EKLF-mediated activation and repression at erythroid and megakaryocytic 
gene loci. 
 
  
Δ221EKLF mice are an excellent model to study separable chromatin remodeling 
and ß-globin gene transcription in vivo 
 
 I have generated mice expressing a unique domain of EKLF that uncouples 
chromatin remodeling and transactivation of β -globin transcription in an intact animal 
model.  Utilizing these animals, I have shown in Chapter 3 that expression of Δ221EKLF 
cannot rescue the EKLF-null phenotype.  Similar to EKLF-null mice, the Δ221EKLF 
mice succumb in utero at E15.5 of gestation, partially as a result of severe anemia.  This 
observation is supported by low levels of β-globin transcripts in Δ221EKLF erythroblasts.  
In contrast to lack of EKLF, expression of Δ221EKLF restores DNase I HS at the β-
globin promoter and induces H3 acetylation at the β-globin promoter.  Thus, chromatin 
remodeling and activation at the β-globin promoter has been uncoupled in vivo.  
Furthermore, the Δ221EKLF mice provide a unique opportunity in which to dissect the 
determinants required for chromatin remodeling and histone modification from those 
essential for β-globin gene transcription in vivo. 
 
EKLF has been shown to associate with a SWI/SNF chromatin remodeling 
complex.  EKLF interaction with Brg1, the ATP-catalytic core of the E-RC1, results in 
chromatin remodeling of a chromatinized β-globin template (Armstrong et al., 1998; 
Kadam et al., 2000).  Additionally, Δ221EKLF and Brg1 interaction has been confirmed 
by in vitro studies in our laboratory (Brown et al., 2002).  However, evidence for EKLF 
interaction with Brg1 at the β-globin in vivo is still lacking.  Thus, the Δ221EKLF mice 
are the ideal reagents in which to explore this question in vivo.  I propose to 
immunoprecipitate EKLF and Brg1 in fetal liver erythroblasts to confirm this interaction 
in vivo. 
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What is the role of Δ221EKLF in erythroid-specific transcription factories? 
 
Work from Fraser’s group has focused on understanding how genes migrate to 
specialized compartments in the nucleus for transcription called transcription factories 
(Osborne et al., 2004).  These transcription factories are discrete foci containing nascent 
RNA production and high concentrations of RNA PolII.  Using a combination of 
techniques including three-dimensional (3D) fluorescence in situ hybridization (FISH), 
immunofluorescence, and chromosome conformation capture (3C) assays, their 
laboratory has provided support for the existence of such discrete factories.    In these 
studies, they have shown that the β-globin gene is transcribed in the same factory as 
AHSP, a gene that is similarly expressed in the erythroid cell.  These genes are separated 
by more than 50 mega bases on murine chromosome 7.  Furthermore, they have shown 
that genes present on different chromosomes such as the β- and α-globin genes, also co-
localize in the same transcription factory but at a lower frequency than genes linked in cis 
(Osborne et al., 2004). 
 
The idea of a discrete foci dedicated to transcription is plausible given that the 
number of factories visible in the nucleus is less than the numbers of expressed genes 
(Obsorne et al., 2004).  However, it is highly tempting to speculate on the factor(s) that 
recruit the genes to the specialized factories.  It would be interesting to determine if 
EKLF is co-localized with erythroid-specific genes such as AHSP.  Our laboratory 
currently has an on-going collaboration with the Fraser group to address this key question.  
Furthermore, studies should be extended to include the role of Δ221EKLF in these 
transcription factories. 
 
 
Is Δ221EKLF sufficient for formation of the Active Chromatin Hub (ACH)? 
 
High-level expression of the β-globin genes requires the upstream enhancer LCR.  
The precise mechanism of how the LCR functions to enhance transcription remains 
unsettled; however, it is relatively agreed upon that it involves communication between 
the LCR and the promoter.  Indeed, establishment of the chromosome conformation 
capture or 3C technique has greatly advanced our knowledge of this communication.  
Using the 3C technique, the Grosveld and Fraser groups have determined that the LCR 
moves in close proximity to actively transcribed genes, forming a structure called the 
active chromatin hub (ACH).  The ACH is a spatial configuration of the locus in which 
the LCR loops toward the active β-globin genes (Tolhuis et al., 2002).  Moreover, EKLF, 
along with GATA-1 but not NF-E2, has been shown to be required for ACH formation 
(Palstra et al., 2003; Vakoc et al., 2005; Kooren et al., 2007).  Thus in the absence of 
EKLF, a substructure is formed consisting of the regions outside of the locus and part of 
the LCR but does not contain the genes (Palstra et al., 2003).  A recent study from 
Bresnick’s group has demonstrated that the chromatin remodeling factor, Brg1, is 
required for loop formation between the LCR and the β-globin promoter (Kim et al., 
2009).  Despite these advances in our knowledge on LCR/β-globin promoter interactions, 
there are still many unanswered questions.  Is chromatin remodeling mandatory for 
LCR/β-promoter interaction via looping? Results from mutant BRG1 mice imply this is a 
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requirement (Kim et al., 2009).  If yes, I hypothesize that Δ221EKLF is sufficient to form 
the ACH given this domain retains full chromatin remodeling activity.  Is active gene 
transcription an absolute requirement for ACH formation?  If yes, I hypothesize that 
Δ221EKLF would be insufficient to establish the ACH given that Δ221EKLF cannot 
activate β-globin gene transcription.  Whatever the results, it would be interesting to 
know the determinants of EKLF required for ACH formation in vivo.    
 
 
Does Δ221EKLF regulate other megakaryocytic genes in vivo? 
 
 In Chapter 4, I reported on new and interesting results demonstrating that 
expression of Δ221EKLF alone is sufficient to block expansion of megakaryocytic 
progenitors observed with complete loss of EKLF.  This inhibition of megakaryopoiesis 
occurs, at least in part, by repression of Fli-1, a key regulator of megakaryocytic 
differentiation.  Results from my ChIP analysis of the Fli-1 promoter suggest that 
Δ221EKLF directly regulate Fli-1 expression in vivo through a mechanism involving 
recruitment of a Sin3A-containing repressor complex to the Fli-1 promoter.  These 
observations are contrasted with previous studies in cell lines that demonstrated 
sumoylation of EKLF at lysine 74 inhibits megakaryopoiesis through recruitment of a 
Mi-2β-containing complex (Siatecka et al., 2007).  It is of interest to note that Mi-2β is 
not part of any Sin3A-containing corepressor complex (Downes et al., 2000).  Thus, my 
results are consistent with the idea that sumoylation of EKLF is not the only mechanism 
for inhibition of megakaryopoiesis in vivo, as Δ221EKLF domain lacks the lysine 74 
region. 
 
 I presented three potential, but not mutually exclusive, models by which 
Δ221EKLF could inhibit megakaryocytic differentiation.  Although my studies have 
provided support for the model in which Δ221EKLF inhibits megakaryopoiesis by 
directly repressing Fli-1 expression levels in vivo, it would be interesting to explore the 
other potential models.  It is possible EKLF, or Δ221EKLF, could directly regulate other 
megakaryocytic genes, such as glycoprotein (GP) IX.  I propose studies in which the 
expression of GpIX is determined in Δ221EKLF erythroblasts compared to wild-type and 
EKLF-null erythroblasts.  I would expect the expression level of GpIX to be reduced in 
Δ221EKLF and wild-type erythroblasts as compared to EKLF-null erythroblasts.  It is 
possible we may not see a significant difference in expression of GpIX in wild-type, 
Δ221EKLF, and EKLF-null cells.  Explanations for this observation are i) GpIX is not a 
direct target of EKLF-mediated repression or ii) GpIX expressions needs to be 
determined in the context of megakaryocytic progenitors only.  Additionally, using ChIP 
analysis, we should examine the binding of Δ221EKLF at GpIX promoter.  If Δ221EKLF 
regulates GpIX, we expect to see Δ221EKLF protein enrichment at the gene promoter.  
These future studies would provide significant information on the role of Δ221EKLF in 
the regulation of megakaryocytic genes. 
 
 Results from in vitro and cellular studies provide evidence for EKLF and Fli-1 
interactions, and this protein-protein interaction may play a role in repression of 
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megakaryopoiesis.  However, evidence for this interaction in vivo is still lacking.  It is 
possible EKLF inhibits megakaryopoiesis by preventing Fli-1 protein binding to its target 
genes through protein-protein interaction.  Studies in MEL cell lines have shown that Fli-
1 occupancy at megakaryocytic gene promoters is increased with EKLF knock-down.  
These studies, however, did not confirm EKLF-Fli-1 interaction as the mechanism for 
this observation.  A confirmatory experiment would be to immunoprecipitate Δ221EKLF 
and Fli-1 proteins in vivo. 
 
 In conclusion, the results in this study provide novel and interesting insights in to 
the in vivo role of the chromatin remodeling domain of EKLF in definitive hematopoietic 
cells.  The results are consistent with the idea that expression of a truncated Δ221EKLF 
protein is sufficient to remodel the local chromatin architecture at the β-globin promoter; 
however, expression of the Δ221EKLF protein alone is not sufficient to transactivate β-
globin gene transcription in vivo.  Furthermore, the current study supports a role for 
Δ221EKLF in repression of the megakaryocytic progenitor expansion observed with 
complete loss of EKLF.  Future experiments should be directed at exploring the role of 
Δ221EKLF in β-globin LCR/promoter interaction and transcription of erythroid- and 
megakaryocytic-specific genes. 
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Gene  Gene symbol  Signal log ratio  
            (null/wt) 
 
SRY-box containing gene 2    Sox2   6.1 
 
acetyl-Coenzyme A synthetase 2    Acas2l   4.2 
 
calcium channel, voltage-dependent   Cacna1b  4.0 
 
benzodiazapine receptor associated protein 1 Bzrap1   2.3 
 
inhibitor of DNA binding 4    Id4   1.7 
 
potassium voltage-gated channel   Kcnq5   1.7 
  
erythroid differentiation regulator 1   Erdr1   1.4 
 
eukaryotic translation initiation factor 2  Eif2s3y  1.3 
 
insulin-like growth factor binding protein 1  Igfbp1   1.3 
 
talin 1       Tln1   1.3 
 
erythropoietin receptor    Epor   -1 
 
ankyrin repeat and  BTB (POZ)    Abtb1   -1.1 
 
eosinophil-associated, ribonuclease   Ear1   -1.1 
 
myeloblastosis oncogene-like 2   Mybl2   -1.1 
 
transportin 2 (importin 3, karyopherin beta 2b) Tnpo2   -1.1 
 
B-cell CLL/lymphoma 11A (zinc finger protein) Bcl11a   -1.2 
 
B-cell translocation gene 2, anti-proliferative Btg2   -1.2 
 
calmodulin regulated spectrin-associated protein Camsap1l1  -1.2 
 
cyclin-dependent kinase inhibitor 2D   Cdkn2d  -1.2 
 
lamin A      Lmna   -1.2 
 
Table A.1. Putative EKLF-dependent genes. 
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Gene   Gene symbol  Signal log ratio  
          (null/wt) 
 
aminolevulinic acid synthase 2, erythroid  Alas2   -1.3 
 
biliverdin reductase B     Blvrb   -1.3 
 
STEAP family member 3    Steap3   -1.3 
 
synuclein, alpha     Snca   -1.5 
 
ankyrin repeat domain 9    Ankrd9  -1.7 
 
erythrocyte protein band 4.2    Epb4.2   -1.8 
 
aminolevulinate, delta-, dehydratase   Epb4.2   -1.8 
 
aminolevulinate, delta-, dehydratase   Alad   -1.9 
 
eukaryotic elongation factor-2 kinase   Eef2k   -1.9 
 
E2F transcription factor 2    E2f2   -2.4 
 
erythrocyte protein band 4.1    Epb4.1   -2.4 
 
Kruppel-like factor 1 (erythroid)   Klf1   -2.5 
 
ankyrin 1, erythroid     Ank1   -2.6 
 
LIM domain only 2     Lmo2   -2.5 
 
Kruppel-like factor 3 (basic)    Klf3   -2.8 
 
transferrin receptor     Tfr   -2.8 
 
SRY-box containing gene 6     Sox6   -3.4 
 
Duffy blood group     Dfy   -3.8 
 
erythrocyte protein band 4.9    Epb4.9   -5.1 
 
erythroid associated factor    Eraf; AHSP  -7.2 
 
Table A.1 (continued). 
EF 
D
C
Δ
Δ
164EKLF
6611 bps
1000
2000
3000
4000
5000
6000
BsaI 1291
AflIII 2251
DraII 2654
XhoI 2663
SalI 2669
HindIII 3255
NheI 3312
AgeI 3374
SacII 3530
DraII 3542
DraII 3590
BsaI 3651
Af lIII 3709
EcoRI 3971
NheI 4080
AgeI 4223
SpeI 4358
DraII 4526
XbaI 5506
DraII 5847
XhoI 5853
EcoRI 6135
NotI 6386
SacII 6396
Amp
164EKLF
loxP
Neo
loxP
221EKLF 
6440 bps
1000
2000
3000
4000
5000
6000 BsaI 1291
AflIII 2251
DraII 2654
XhoI 2663
SalI 2669
HindIII 3255
NheI 3312
DraII 3371
DraII 3419
BsaI 3480
AflIII 3538
EcoRI 3800
NheI 3909
AgeI 4052
SpeI 4187
DraII 4355
XbaI 5335
DraII 5676
XhoI 5682
EcoRI 5964
NotI 6215
SacII 6225
Amp
221EKLF                          
loxP
Neo
loxP
E
F 
D
C
Δ
Δ
253EKLF
6344 bps
1000
2000
3000
4000
5000
6000 BsaI 1291
AflIII 2251
DraII 2654
XhoI 2663
SalI 2669
HindIII 3255
NheI 3312
BsaI 3384
AflIII 3442
EcoRI 3704
NheI 3813
AgeI 3956
SpeI 4091
DraII 4259
XbaI 5239
DraII 5580
XhoI 5586
EcoRI 5868
NotI 6119
SacII 6129
Amp
253EKLF
loxP
Neo
loxP
E
F 
D
C
Δ
Δ
Δ164EKLF Δ221EKLF Δ253EKLF  
 
 
 
NheI
MW 1    2    3
AgeI/
DralII
1    2    3
EcoRI/
XbaI
1    2    3
HindIII/
EcoRI
1    2    3
AflIII
MW  1    2    3
EcoRI
1    2    3
HindIII/
SpeI
1    2    3
SacIII/
SpeI
1    2    3
BsaI
MW 1    2    3
NotI/
SalI
1    2    3
XhoI
1    2    3
XbaI/
SalI
1    2    3
23.1 kb
9.4 kb
6.6 kb
2.3 kb
2.0 kb
1.4 kb
1.1 kb
0.87 kb
06.0 kb
 
 
Figure A.1. Confirmation of the mini-targeting vectors.  The top panel shows the 
plasmid maps of the mini targeting vectors, HA-Δ164EKLF, HA-Δ221EKLF, and HA-
Δ253EKLF, respectively. The bottom panel is representative agarose gels after digestion 
of the mini targeting vectors with the restriction enzymes. Lane 1 = HA-∆164EKLF; lane 
2 = HA-∆221EKLF; lane 3 = HA-∆153EKLF.  The predicted fragments are given in 
Appendix Table A.2.
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Enzyme         Δ164 (1)         Δ221 (2)         Δ253 (3) 
 
 
NheI    5.8   5.8   5.8 
    0.8   0.6   0.5 
 
AgeI/DraIII   3.2   3.8   3.7 
    2.6   2.6   2.6 
    0.9 
 
EcoRI/XbaI   4.4   4.3   4.2 
    1.5   1.5   1.5 
    0.6   0.6   0.6 
 
HindIII/EcoRI   3.7   3.7   3.7 
    2.2   2.2   2.2 
    0.7   0.6   0.5 
 
AflIII    5.2   5.2   5.2 
    1.5   1.3   1.2 
 
EcoRI    4.4   4.3   4.2 
    2.2   2.2   2.2 
 
HindIII/SpeI   5.5   5.5   5.5 
    1.1   0.9   0.8 
 
SacIII/SpeI   3.7   4.4   4.3 
    2.0   2.0   2.0 
    0.8  
 
BsaI    4.3   4.3   4.3 
    2.3   2.2   2.1 
 
NotI/SalI   3.7   3.5   3.4 
    2.9   2.9   2.9 
 
XhoI    3.4   3.4   3.4 
    3.2   3.0   2.8 
 
XbaI/SalI   3.8   3.8   3.8 
    2.8   2.7   2.6 
 
  
Table A.2. Predicted fragment size with restriction enzyme digestion. 
A. 5’ Southern blot probe 
 
CTAGCTAAAGCCTTTCTTATTAATGCCAAAAGAACTGAAGCAGGAAATCA
CGGTGGTTACACAGCCCAGCACCTAAGCCCAATTTACAGGACAAGGCTCA
TTTTTATTATTAGAGCTCCTTTGGTAACAGAGAAGGCTGCTCACAGCCAGC
ATGCTCAAGGTTGTATAAAGCACAACAATGTTATTTGTCTTCAGAAAAAC
ATCTGAGGTGTGGGAACATCATTTACCCTGACTATGCT 
 
 
B. 3’ Southern blot probe 
 
AATTCGCCCTTAAGGGCCAGAACTTGGAGCGCCTTAGAAGTCACGTGACA
GCCAATGCCCAAGGGAGAGGCGTGTCCACGGATGAAGCCTATCCGGAGC
TGAGTCGGCCAGAAGCGGGAGGACGGGGCGGGGAGGACATTGGAGGAG
GCGGGGTCCGCTTGTGGGACAACTTCATAGGAAGCCCCGCCTCCGTATTG
GGCCTGGCGGGCTTCGTCTCCACCCTCGCGAAGCCGGGACACAGATCTCT
TCGGTTTTTAGGGGAAGTTCATCTGAATCTCGTGACCCGGCTGTCCCCGGG
TCTTTTAGAGTCCATTGCTGTCGCCTCATGGCAACACTGAGATCGCTGCTG
CTGGCTGCGCTGCTGTGGGTCCCTGCCGAAGCCCTGAGCTGCTATGGGGA
CTCCGGGCAGCCTGTGGATTGGTGAGTAAGTAGTCGCGGGACTGTCCCCC
GCACACTGCCTGGGGACCGGCGCGGGAATCCAAAAAACCTCAGATTCCTT
CTCTCCCCCAACCTCATGTCTTCACGGACCTCCAGGTTCGTGGT 
 
 
Figure A.2. Sequences of Southern blot probes used in screening targeted ES cells 
and genotyping of animals.  (A) The 239 bp 5’ probe was used with EcoRV digest to 
identify an 8.7 kb wt band and 6.8 kb KI band.  (B) The 543 bp 3’ probe was used with 
NheI digest to identify an 11.1 kb wt band and 9.1 kb KI band. 
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Buffer      Composition 
 
 
Cell Lysis     10mM Tris pH 8.0 
10mM NaCl 
0.2% NP40 
Add Protease inhibitors (Roche) and PMSF 
before use. 
 
Nuclei Lysis     50mM Tris pH 8.0 
10mM EDTA 
1% SDS 
Add Protease inhibitors (Roche) and PMSF 
before use. 
 
IP Dilution Buffer    20mM Tris pH 8.0 
2mM EDTA 
150mM NaCl 
1% Triton X-100 
0.01% SDS 
Add Protease inhibitors (Roche) and PMSF 
before use. 
 
IP Wash Buffer 1    20mM Tris pH 8.0 
2mM EDTA 
50mM NaCl 
1% Triton X-100 
0.1% SDS 
 
IP Wash Buffer 2    10mM Tris pH 8.0 
1mM EDTA 
0.25M LiCl 
1% NP40 
1% Deoxycholic acid 
 
Elution Buffer     100mM NaHCO3 
1% SDS (use high quality SDS) 
 
 
 
Table A.3. Buffer composition used in ChIP analysis. 
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Table A.4. Primers used for ChIP analysis. 
 
Region     Primer sequence     Reference 
 
 
HS2    5’-AGTCAATTCTCTACTCCCCACCCT-3’   Kiekhaefer et al., 2002 
     5’-ACTGCTGTGCTCAAGCCTGAT-3’ 
 
IVR    5’-GTATGCTCAATTCAAATGTACCTTATTTTAA-3’  Kiekhaefer et al., 2002 
     5’-TTACCTCTTTATTTCACTTTTACACATAGCTAA-3’ 
 
βmaj pro   5’-CAGGGAGAAATATGCTTGTCATCA-3’   Kiekhaefer et al., 2002 
     5’-GTGAGCAGATTGGCCCTTACC-3’ 
 
βmaj ex3   5’-GCCCTGGCTCACAAGTACCA-3’    Kiekhaefer et al., 2002 
     5’-TTCACAGGCAAGAGCAGGAA-3’ 
 
AHSP    5’-CTAACTCCAGGGAAGCCTCACC-3’    Pilon et al., 2006  
     5’-TTTGTGTGTCTTCTGCACTAAGCG-3’ 
 
Fli-1    5’-CGTGGACCCCGTCATTGTT-3’    Frontelo et al., 2007 
     5’-GCACTGCGCACACAGGATACT-3’ 
 
RPII215   5’-GCGAATCTATAAAGGGCGTCACT-3’    Kiekhaefer et al., 2002 
     5’-TCGGCGCTTCTGAGGAGA-3’ 
 
α-globin pro   5’-TGACCAAGGTAGGAGGATACTAACTTCT-3’  Anquita et al., 2004 
     5’-TTGCCCGGACACACTTCTTAC-3’ 
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Table A.5. Primers used for real time RT-PCR analysis. 
 
 Gene     Primer sequence     Reference 
 
 
Alas 2    5’-CACCTATGCTTAAGGAGCCA-3’   Drissen et al., 2005  
      5’-CAGAAGCACACAGGAAAGCA-3’ 
  
Alad    5’-CTTTGATCTCAGGACTGCTG-3’   Drissen et al., 2005 
5’-AACAGCTGCGGTGCAAAGTA-3’ 
 
Pbgd    5’-TACTTCTGGCTTCCAAGTGC-3’   Drissen et al., 2005  
      5’-CAAGGTGAGGCATATCTTCC-3’ 
 
Urod    5’-ATCCCTGTGCCTTGTATGCA-3’   Drissen et al., 2005 
      5’-AGGTTGGCAATTGAGCGTTG-3’ 
 
Cpox    5’-CAATTTGAAGCCAGTCCGTG-3’   Drissen et al., 2005 
5’-CTGGACTAGAACTCCCTTTG-3’ 
  
Ppox    5’-ATTCCAGCTTCAGAGCTCAG-3’   Drissen et al., 2005 
      5’-TACTGCAGATTCACCACAGC-3’ 
 
Fech    5’-ACCAGTGACCACATTGAGAC-3’   Drissen et al., 2005 
      5’-GGCCTTGGAGAACAATGGAT-3’ 
 
AHSP    5’-GGATCAGCAGGTCTTTGATG-3’   Drissen et al., 2005 
      5’-AGAGTACTCAGCTCTTGCTG-3’ 
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Gene     Primer sequence     Reference 
 
 
Epb4.9    5’-TGCTCAAGACCCAAGGCTTA-3′   Drissen et al., 2005 
      5’-TCCTATCTGGTTTTGCCTGG-3′ 
 
GAPDH   5’-CCTGCCAAGTATGATGACAT-3′   Drissen et al., 2005 
      5’-GTCCTCAGTGTAGCCCAAG-3′ 
 
Ankyrin   5’-CTCCAGCCGGACCTGATAGAG-3′   Nilson et al., 2006 
      5′-GAACACGTGCGACCCTTCAGTAG-3′ 
 
Band 3    5′-CACAGTGCCTCTCCGTCGTCTCATC-3′  Nilson et al., 2006 
 5′-CCTTCCCCACCCACAGCCATAACAC-3′ 
 
BKLF    5’-GAAATGTCACCCCCTTTAATGAAC-3′  Funnell et al., 2007 
      5’-CACGATGACGGAAGGATGGT-3′ 
 
Fli-1    5’-CAACCAGCCAGTGAGAGTCA-3′    
      5’-GCCCACCAGCTTGTTACATT-3′ 
 
β-globin mRNA  5’-TTTAACGATGGCCTGAATCACTT-3′ 
      5’-CAGCACAATCAGATCATATTGC-3′ 
 
β-globin 1o transcripts  5’-CTTCTCTCTCTCCTCTCTCTTTCTCTAATC-3′ 
      5’-AATGAACTGAGGGAAAGGAAAGG-3′ 
 
 
Table A.5 (continued). 
WT Δ221 KO
BFU-E
CFU-GM
CFU-GEMM
A B C
G
FED
H I
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Figure A.3.  Fetal liver hematopoietic progenitors.  Fetal liver cells were plated in 
methocellulose medium and colonies were scored after 14 days of growth.  Panels a-c: 
burst-forming unit-erythroid (BFU-E).  Panels d-f: colony-forming unit-granulocyte-
monocyte (CFU-GM).  Panels g-i: colony-forming unit-granulocyte-erythroid-monocyte-
megakaryocyte. 
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